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ABSTRACT 
Steven David Rhodes 
 
DISSECTING THE CELLULAR AND MOLECULAR MECHANISMS 
UNDERLYING BONE DEFECTS IN NEUROFIBROMATOSIS TYPE 1 
 
Skeletal manifestations including short stature, osteoporosis, 
kyphoscoliosis, and tibial dysplasia cumulatively affect approximately 70% of 
patients with neurofibromatosis type 1 (NF1). Tibial pseudarthrosis, the chronic 
non-union of a spontaneous fracture, is a debilitating skeletal malady affecting 
young children with NF1. These non-healing fractures respond poorly to 
treatment and often require amputation of the affected limb due to limited 
understanding of the causative mechanisms. 
To better understand the cellular and molecular pathogenesis of these 
osseous defects, we have established a new mouse model which recapitulates a 
spectrum of skeletal pathologies frequently observed in patients with NF1. Nf1flox/-
;Col2.3Cre mice, harboring Nf1 nullizygous osteoblasts on a Nf1+/- background, 
exhibit multiple osseous defects which are closely reminiscent of those found in 
NF1 patients, including runting (short stature), bone mass deficits, spinal 
deformities, and tibial fracture non-union. 
Through adoptive bone marrow transfer studies, we have demonstrated 
that the Nf1 haploinsufficient hematopoietic system pivotally mediates the 
pathogenesis of bone loss and fracture non-union in Nf1flox/-;Col2.3Cre mice. By 
vii 
genetic ablation of a single Nf1 allele in early myeloid development, under the 
control of LysMCre, we have further delineated that Nf1 haploinsufficient myeloid 
progenitors and osteoclasts are the culprit lineages mediating accelerated bone 
loss. Interestingly, conditional Nf1 haploinsufficiency in mature osteoclasts, 
induced by CtskCre, was insufficient to trigger enhanced lytic activity. These data 
provide direct genetic evidence for Nf1’s temporal significance as a gatekeeper 
of the osteoclast progenitor pool in primitive myelopoiesis. 
On the molecular level, we found that transforming growth factor-beta1 
(TGF-β1), a primary mediator in the spatiotemporal coupling of bone remodeling, 
is pathologically overexpressed by five- to six- fold in both NF1 patients and in 
mice. Nf1 deficient osteoblasts, the principal source of TGF-β1 in the bone 
matrix, overexpress TGF-β1 in a gene dosage dependent fashion. Moreover, 
p21Ras dependent hyperactivation of the Smad pathway accentuates responses 
to pathological TGF-β1 signals in Nf1 deficient bone cells. As a proof of concept, 
we demonstrate that pharmacologic TβRI kinase inhibition can rescue bone 
mass defects and prevent tibial fracture non-union in Nf1flox/-;Col2.3Cre mice, 
suggesting that targeting TGF-β1 signaling in myeloid lineages may provide 
therapeutic benefit for treating NF1 skeletal defects. 
 
Feng-Chun Yang, M.D., Ph.D., Chair 
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CHAPTER 1. INTRODUCTION 
 
Neurofibromatosis type 1 
Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic 
disorder affecting one in 3,500 persons worldwide [1]. NF1 results from mutations 
in the NF1 tumor suppressor gene located on the long arm of chromosome 17 at 
17q11.2 [2, 3]. Containing 60 exons and spanning greater than 300kb of genomic 
DNA, the NF1 gene encodes the Ras-GTPase activating protein neurofibromin, 
which negatively regulates the activity of p21ras (Ras) by accelerating the 
conversion of active Ras-guanosine triphosphate (GTP) to inactive Ras-
guanosine diphosphate (GDP) [2, 3]. Ras proteins lie upstream of multiple 
signaling pathways regulating cell growth, survival, differentiation and 
cytoskeletal function. Active Ras-GTP recruits the serine-threonine kinase Raf-1 
to the plasma membrane, which subsequently activates a series of downstream 
targets such as extracellular signal-regulated kinases (ERKs) (p44/p42 MAPK) 
and phosphatidylinositol 3-kinase (PI-3K) [4, 5]. Loss of one or both functional 
copies of the NF1 allele results in Ras hyperactivation in response to external 
stimuli. This dysregulation of Ras signaling gives rise to the genetic disorder 
neurofibromatosis type I (NF1). 
In 1882, the German pathologist Freidrich von Recklinghausen first 
published his seminal case report documenting “innumerable” cutaneous tumors 
composed of both neurons and fibroblasts, which he called neurofibromas [6]. 
Beyond the pathognomonic cutaneous and plexiform neurofibromas, extensive 
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epidemiological study [1, 7, 8] now shows that NF1 patients suffer a range of 
malignant and non-malignant manifestations including café au lait macules, 
axillary or inguinal freckling, optic gliomas [9, 10], Lisch nodules [11], cognitive 
impairment [12], and cardiovascular disease [13-18]. Children with NF1 have a 
500-fold increased risk of developing juvenile myelomonocytic leukemia (JMML) 
due to loss of heterozygosity (LOH) of the normal NF1 allele [19-21]. 
 
Skeletal manifestations of NF1 
Aside from the aforementioned features, NF1 patients develop a range of 
characteristic skeletal manifestations including osteoporosis [22-27], 
kyphoscoliosis [28-30], short stature [31-33], macrocephaly [32], chest wall 
deformities [34], sphenoid wing dysplasia [8], and pseudarthrosis of the tibia [35-
39]. Osseous defects in NF1 can be subclassified as either generalized or focal 
in nature. Generalized deficits, including reduced bone mineralization and short 
stature, affect greater than half of all NF1 patients collectively. Focal deficits, 
such as dystrophic scoliosis, sphenoid wing dysplasia, and tibial pseudarthrosis, 
occur at a lower frequency, yet carry significant morbidity. 
Osteoporosis 
Although osteoporosis is recognized as a major source of morbidity in the 
aging population, it is quite rare among children and adolescents and was 
previously unrecognized as a significant complication of NF1. In 2001, Illes and 
colleagues were the first to document reduced bone mineral density (BMD) in 
NF1 patients with scoliosis requiring surgical correction, noting “very soft 
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vertebral bone” upon intraoperative assessment [30]. Measurement of lumbar 
spine BMD by peripheral dual energy x-ray absorptiometry (pDEXA) revealed a 
mean z-score of -2.5. Moreover, patients with the most pronounced reductions in 
BMD tended to have increased severity of scoliosis [30], a finding which was 
later corroborated in a larger cross-sectional study of 104 NF1 patients [22]. A 
consensus of published literature suggests that BMD may be significantly 
reduced in up to 50% of children and adolescents with NF1 [22, 24-26]. 
Consistent with these findings, children and adolescents with NF1 also 
exhibit significantly increased deoxypyridinoline (Dpd)/pyridinoline (Pyd) ratios 
[40], an established biomarker of bone resorption that is often increased in 
patients with a variety of high bone turnover states including osteoporosis, 
Paget’s disease, and hyperparathyroidism [41-43]. While the consequences of 
low BMD in the pediatrics NF1 population remain unclear, it has been 
hypothesized that increased bone resorption and reduced BMD could lead to the 
accumulation of clinically undetected microfractures in patients with NF1, 
compromising the mechanical integrity of the bone later in life. Indeed, Tucker 
and colleagues found that the risk of fracture among adults with NF1 was 
markedly increased as compared to their unaffected siblings and spouses [27]. 
41 fractures were documented among 24 out of 72 NF1 patients, as compared to 
just six fractures among six individuals out of 73 unaffected siblings. Moreover, 
among the NF1 patient cohort, 24 pathological fractures (associated with minimal 
trauma) were documented in 14 individuals, whereas no pathological fractures 
were reported in the unaffected cohort [27]. More recently, a controlled study of 
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460 neurofibromatosis patients conducted in Finland [44] confirmed that adults 
with NF1 ages 41 years and older had a 5.2-fold increased risk of fracture versus 
age-matched controls without NF1. Children with NF1 ages 17 and under had a 
3.4-fold increased risk ratio for fractures [44]. 
Although NF1 associated osteopenia and osteoporosis commonly present 
during childhood, there are currently no clinical trials which support the use of 
traditional osteoporotic drugs (bisphosphonates, PTH, etc.) in this population 
[36]. Despite evidence of reduced Vitamin D levels in a subset of NF1 patients 
[45], supplementation with calcium and Vitamin D did not significantly improve 
BMD z-scores after 2 years follow-up [46]. Collectively, these findings are 
suggestive of a generalized metabolic bone defect due to functional inactivation 
of neurofibromin. 
Vertebral defects 
Gould and Weiss first called attention to the high incidence of spinal 
deformities in patients with NF1 in the early 1900s [47, 48]. Vertebral defects are 
observed in between 10-77% of NF1 patients according to varying clinical reports 
[49-51] and approximately 2% of all pediatric scoliosis cases are associated with 
NF1[52]. Scoliosis is sub-classified as either non-dystrophic or dystrophic, based 
on the absence or presence of various radiographic findings [53]. Non-dystrophic 
scoliosis in NF1 mimics idiopathic scoliosis in the general population, but 
presents earlier and is associated with a higher risk of pseudarthrosis after spinal 
fusion [54]. Dystrophic scoliosis refers to dysplastic osseous changes with rapid 
onset and progression. Studies have identified characteristic radiographic 
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features associated with dystrophic scoliosis in NF1 which include rib penciling, 
short-segment sharply angulated curves involving four to six vertebrae, vertebral 
rotation, scalloping of the vertebral margins, spindling of the transverse 
processes, pedicle defects, and widening of the spinal canal [53, 55]. Dystrophic 
scoliosis can be a debilitating condition for children and adolescents with NF1, 
with the potential to degenerate rapidly to neurological impairment. Orthopedic 
manipulation is also associated with a risk of pseudarthrosis in the affected 
vertebrae following surgical intervention [28, 56]. 
Congenital pseudarthrosis of the tibia (CPT) 
Congenital pseudarthrosis, first described by James Paget in 1891, is a 
rare orthopedic condition characterized by anterolateral bowing of the tibia with 
tapering at the defective site [57]. While the overall incidence is only 1:140,000-
1:250,000 live births [58], remarkably, 50-80% of all congenital tibial 
pseudarthrosis cases have been reported to involve mutations in the NF1 gene 
[59-62]. Fractures can occur spontaneously or following minimal trauma. Bone 
healing is insufficient, resulting in persistent fibrous non-union even after multiple 
surgeries. Faced with limited and ineffective treatment options, elective limb 
amputation is often required to restore mobility. 
Fibrous hamartoma tissues surgically excised from pseudarthrosis lesions 
associated with NF1 maintain a mesenchymal lineage phenotype, expressing the 
cell surface markers CD44 and CD105, but are negative for CD45 and CD14 
[63]. Although they express BMP receptors, they do not undergo osteoblastic 
differentiation ex vivo in response to BMP [63]. In addition to defective 
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osteogenesis, osteoclasts are abundant in pseudarthrosis tissue [62, 64, 65]. 
Furthermore, Cho and colleagues reported that fibrous hamartoma cells 
harvested from pseudarthrosis tissue expressed a significantly increased levels 
of receptor activator of nuclear factor kappa-B ligand (RANKL) and lower levels 
of osteoprotegerin (OPG) as compared to control tibial periosteal cells, 
enhancing osteoclast differentiation in co-culture with Raw264.7 cells [63]. 
Collectively, these findings suggest that the pathogenesis of NF1 tibial 
pseudarthrosis is likely complex, involving the heterotypic interaction of 
dysfunctional mesenchymal stem cells (MSCs) and/or osteoblasts as well as 
excessive osteoclast bone resorption. Yet fully dissecting the cellular and 
molecular mechanisms of pseudarthrosis and other NF1 osseous deficits will 
require the generation of new mouse models which accurately recapitulate 
multiple skeletal phenotypes seen in the human disease. 
 
Modeling NF1 osseous defects in the mouse 
Mouse models have been critical in facilitating key insights into the role of 
Nf1 in bone biology and as a platform for preclinical testing of potential 
pharmacologic therapies (Table 1). Nf1-/- mice die in utero before day 13 of 
gestation due to heart developmental abnormalities associated with excessive 
proliferation and premature apoptosis of the endocardium [66]. Additionally, 
adoptive transfer experiments with Nf1-/- fetal liver cells have been shown to 
consistently induce a myeloproliferative disease (MPD) similar to JMML seen in 
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NF1 patients [67, 68]. For these reasons, Nf1-/- mice are not suitable for bone 
studies. 
 Nf1+/- mice exhibit cytokine hypersensitivity in multiple myeloid lineages 
including myeloid progenitors, mast cells, and osteoclasts. Osteoclasts derived 
from both human NF1 patients and Nf1+/- mice display multiple gain-in-functions 
including increased proliferation, survival, and bone resorption, which are 
associated with more severe osteoporotic bone loss in Nf1+/- mice induced by 
ovariectomy (OVX) pro-resorptive stress [69-71]. These phenotypes are 
associated with elevated p21ras-GTP and Akt phosphorylation in response to M-
CSF stimulation. Intriguingly, genetic intercross with mice deficient in class 1a PI-
3K (p85α) attenuated Akt phosphorylation and restored aberrant Nf1+/- osteoclast 
functions to WT levels [69]. Collectively, these findings provided seminal 
evidence that hyperactivity of p21ras and PI3K cooperate to alter Nf1 
haploinsufficient osteoclast functions. 
 Downstream of hyperactivated Ras, Rho GTPases act as molecular 
gatekeepers, cycling between inactive-GDP and active-GTP-bound forms to 
modulate osteoclast cytoskeletal functions. We previously demonstrated that the 
Rho-GTPase Rac1 is a crucial Ras effector mediating aberrant osteoclast 
migration and f-actin rearrangement within the podosomes of Nf1+/- osteoclasts 
[72]. Genetic disruption of Rac1 in Nf1+/- mice attenuated elevated levels of 
phosphorylated extracellular signal-regulated kinases (Erk1/2) while normalizing 
Nf1 haploinsufficient cytoskeletal phenotypes and bone resorptive activity. 
Analogous results were achieved after application of a pharmacologic MEK 
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inhibitor (PD98059), suggesting that Rac1-GTPase hyperactivation contributes in 
turn to excessive activation of the Ras-PI3K-Erk signaling axis in Nf1+/- 
osteoclasts [72]. 
Recent studies also show that neurofibromin plays a critical role in 
osteoblast differentiation from mesenchymal stem cells (MSCs). MSCs from 
Nf1+/- mice have increased proliferation and colony forming unit-fibroblast (CFU-
F), but impaired osteoblast differentiation as confirmed by alkaline phosphatase 
staining, and reduced mRNA levels of osteoblast specific markers such as 
osteocalcin and osteonectin [73]. Retroviral transduction of Nf1+/- MSPCs with 
NF1 GTPase activating related domain (NF1 GRD) was sufficient to rescue the 
impaired osteoblast differentiation in these cells [73]. 
While osteoclasts and osteoblasts cultured ex vivo from Nf1+/- mice exhibit 
aberrant differentiation and function, surprisingly, bone mineral density and 
peripheral quantitative computed tomography (pQCT) analysis show no 
difference in bone mass or microarchitecture as compared to WT controls [74]. 
This finding suggests that Nf1 heterozygosity alone may be insufficient to 
spontaneously recapitulate the full spectrum of skeletal manifestations observed 
in the human disease. In an effort to more accurately recapitulate the full 
spectrum of osseous defects observed in the human disease, Cre-lox technology 
has been utilized by various laboratories to achieve conditionally Nf1 nullizygosity 
in select lineages within the mesenchymal hierarchy. 
Elefteriou and colleagues utilized a genetic approach to delete Nf1 in the 
osteoblast lineage by intercrossing Nf1flox/flox mice with α1(I) Collagen Cre 
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transgenic mice and paradoxically found that Nf1 inactivation in osteoblasts led 
to increased bone mass in the vertebral spine [75]. These results are difficult to 
interpret since they represent the antithesis of the osteoporotic phenotype 
observed in human NF1 patients. Moreover, the same authors later reported 
recalcitrant bone healing in the same mice due to deficiencies in osteoblast 
differentiation [76]. For reasons which are still unclear, we have been unable to 
recapitulate the results described by Elefteriou and colleagues in 
Nf1flox/flox;Col2.3Cre mice [77, 78]. 
Kolanczyk and colleagues observed tibial bowing and runting in Nf1flox/flox 
mice with conditional Nf1 nullizygosity in undifferentiated limb bud mesenchyme 
driven by Prx1Cre [79]. While informative, this model remains limited as it does 
not spontaneously recapitulate the osteoporotic manifestations of NF1 patients. 
Clinically, bone mass defects tend to be localized to the load-bearing anatomical 
sites, such as the tibia and spine, where dystrophic deformities most often occur 
[23]. These findings suggest a strong association between the osteoporotic and 
the dystrophic skeletal phenotypes of NF1 which warrants further investigation. 
Regardless of these discrepancies, the inability of various single lineage 
conditional knockout models to recapitulate the full spectrum of NF1 skeletal 
defects suggests that certain manifestations, particularly pseudarthrosis, may 
require the heterotypic interaction of multiple cell lineages with varying gene 
dose. In support of this paradigm, Stevenson and colleagues first demonstrated 
two cases of biallelic NF1 inactivation in the bone tissue by microdissection, 
while patients remained NF1 haploinsufficient in the peripheral blood [80]. More 
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recent case series since corroborated these findings, in which loss of NF1 
heterozygosity (LOH) was documented in four out of 16 patients tested [81]. 
Collectively, these data suggest that localized biallelic NF1 inactivation in either 
osteoblasts or mesenchymal progenitor cells, interacting with other NF1 
haploinsufficient lineages in the bone microenvironment, may pivotally underpin 
the pathological bone repair process in at least a subset of patients with 
pseudarthrosis. 
To model this complex genetic framework, we generated two novel murine 
models (Nf1flox/-;PeriCre and Nf1flox/-;Col2.3Cre mice ), harboring Nf1 nullizygous 
MSCs and osteoblasts, respectively, on a Nf1 heterozygous background. In the 
third chapter of this thesis, we show that Nf1flox/-;PeriCre and Nf1flox/-;Col2.3Cre 
mice closely recapitulate multiple skeletal phenotypes observed in NF1 patients, 
including osteoporosis [78], non-dystrophic and dystrophic vertebral deficits [77], 
and tibial fracture non-union (pseudarthrosis) [78]. Collectively, these findings 
provide strong evidence of a non-cell autonomous mechanism for NF1 osseous 
defects and serve as our platform for investigations of the cellular and molecular 
mechanisms mediating aberrant NF1 bone homeostasis in vivo as described in 
detail in later chapters of this thesis. 
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Species Disease/ Model Conclusion Authors, Date 
Mouse Nf1+/- mice In vitro: Reduced 
osteoblast differentiation. 
Multiple osteoclast gain-in-
functions.  
In vivo: Increased bone 
loss after ovariectomy 
stress. Deficient tibial 
fracture repair. 
(Yu et al., 2005) 
(Yang et al., 2006) 
(Schindeler et al., 
2008) 
Mouse Conditional KO: 
Nf1OB-/- 
(Prx1Cre, 
Col2.3Cre) 
In vitro: Reduced 
osteoblast differentiation 
(Prx1Cre model). 
In vivo: Runting and tibial 
bowing (Prx1Cre model). 
Paradoxically, increased 
bone mass but with bone 
healing defects (Col2.3Cre 
model). 
(Elefteriou et al., 
2006) 
(Kolanczyk et al., 
2007) 
(Wang et al., 2010) 
Human Pseudarthrosis NF1 loss of heterozygosity 
(LOH) in pseudarthrosis 
tissue. 
(Stevenson et al., 
2006) 
Human Osteoporosis Osteoclasts derived from 
the peripheral blood of NF1 
patients show multiple 
gain-in-functions. 
Decreased bone mineral 
density and content in the 
load-carrying anatomical 
regions. 
(Kuorilehto et al., 
2005) 
(Yang et al., 2006) 
(Heervӓ et al., 2010) 
Mouse Conditional KO 
w/ Nf1+/- 
Background: 
Nf1+/-OB-/- 
(Col2.3Cre) 
Decreased bone mass in 
the vertebrae and long 
bones. Severe fracture 
repair deficits compared to 
Nf1OB-/- and Nf1+/- mice. 
Transplantation of WT 
bone marrow rescues 
phenotype. 
(Zhang, Rhodes et 
al., 2011) 
(Wu et al., 2011) 
 
Table 1 
12 
Table 1. Mouse models of NF1 skeletal defects. 
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Nf1 haploinsufficient hematopoietic cells: critical mediators in the 
pathogenesis of bone defects 
 Neurofibromas, the pathognomonic tumors of NF1, are unique with 
respect to their cellular heterogeneity, containing Schwann cells, fibroblasts, 
mast cells, and vasculature [82, 83]. Genetic studies indicate that biallelic loss of 
Nf1 in Schwann cells is necessary but not sufficient for tumor formation. Indeed, 
Yang and colleagues demonstrated that heterozygosity of bone marrow-derived 
cells in the tumor microenvironment is required for neurofibroma genesis in mice 
harboring Nf1 nullizygous Schwann cells [84]. 
 Analogously, Nf1flox/flox;Col2.3Cre mice (harboring conditional nullizygous 
osteoblasts on a WT background) do not exhibit osseous defects [78], implying 
that Nf1 deficiency in osteoblasts alone is insufficient for the full penetrance of 
NF1 skeletal deficits. By contrast, Nf1flox/-;Col2.3Cre mice recapitulate a spectrum 
of boney defects observed in the human disease [77, 78], including runting (short 
stature), low bone mass, vertebral defects, and tibial fracture non-union, 
suggesting that Nf1 haploinsufficiency in at least a subset of lineages within the 
bone microenvironment must be critical to the pathogenesis of these osseous 
features. To establish whether the hematopoietic microenvironment plays a key 
role in recalcitrant fracture healing in Nf1flox/-;Col2.3Cre mice, Wu and colleagues 
transplanted bone marrow mononuclear cells (BMMNCs) from either WT or Nf1+/- 
donor mice into lethally irradiated Nf1flox/-;Col2.3Cre or Nf1flox/flox;Col2.3Cre 
recipients [78]. After four months of hematopoietic reconstitution, the recipient 
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mice underwent three-point bending fracture. The fracture healing process was 
monitored for a duration of four weeks. 
Fracture healing in Nf1flox/flox;Col2.3Cre mice reconstituted with Nf1+/- 
marrow was significantly impaired relative to those receiving WT bone marrow 
cells as confirmed by radiographic and histological analysis. µCT revealed 
significantly reductions in BV/TV fraction in Nf1flox/flox;Col2.3Cre recipients 
transplanted with Nf1+/- bone marrow cells as compared to WT bone marrow. 
Conversely, transplantation of WT bone marrow prevented tibial fracture non-
union normally observed in Nf1flox/-;Col2.3Cre mice (Figure 1). Collectively, these 
data provide rigorous evidence that at least some component of the Nf1 
haploinsufficient bone marrow microenvironment plays an essential role in the 
skeletal manifestations of NF1, particularly in fracture non-union. Still, the specific 
lineage(s) in the hematopoietic system that is(are) critical for the pathological 
bone repair process remains unclear. 
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Figure 1 
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Figure 1. The Nf1 status of the hematopoietic microenvironment 
significantly alters tibial fracture healing in Nf1flox/flox and Nf1flox/-;Col2.3Cre 
mice. Adoptive transfer of Nf1+/- hematopoietic cells to Nf1flox/flox;Col2.3Cre mice 
results in tibial fracture non-union as compared to isogenic controls transplanted 
with WT bone marrow cells. Conversely, adoptive transfer of WT hematopoietic 
cells to Nf1flox/-;Col2.3Cre mice rescues fracture healing deficits in these animals. 
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Transforming growth factor-beta (TGF-β), decoupled bone remodeling, and 
osteoblast/osteoclast dysfunction 
Exacerbating intrinsic imbalances in osteoclast and osteoblast function in 
the context of Nf1 inactivation is the dysregulated secretion of paracrine factors 
including receptor activator of nuclear factor kappa-B ligand (RANKL), 
osteoprotegerin (OPG), and osteopontin (OPN), which further promote excessive 
osteoclastogenesis and osteoclast bone lytic activity [75, 85, 86]. As such, the 
identification and characterization of hyperactive Ras-dependent paracrine 
effector pathways that can be interrupted with currently existing monoclonal 
antibodies or small molecule inhibitors holds strong potential for improving 
skeletal health in the NF1 population. 
Transforming growth factor-beta (TGF-β) is known to be a key regulator of 
bone mass, matrix, and mechanical properties, which in turn impacts the ability of 
bone to resist fracture [87, 88]. Previously, our laboratory established that 
hypersecretion of TGF-β by Nf1+/- mast cells induces neurofibroma phenotypes 
by enhancing Nf1+/- fibroblast proliferation and collagen synthesis via 
hyperactivation of the Ras-c-abl pathway [89]. Although the pivotal role of TGF-β 
in physiological bone turnover has been previously characterized, genetic and 
pharmacologic studies characterizing the potential consequences of hyperactive 
TGF-β signaling with respect to NF1 pathological bone remodeling are lacking. 
Recently, a study by Wang et al. examining tibial fracture healing in 
transgenic mice carrying Nf1 nullizygous osteoblasts (Nf1ob-/- mice) demonstrated 
an increase in TGF-β mRNA expression in Nf1ob-/- calluses compared with WT 
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controls [76]. Intriguingly, local delivery of low-dose lovastatin improved deficits in 
callus strength and maturation in Nf1ob-/- mice [76]. Although lovastatin reduced 
callus TGF-β mRNA expression, its effects are not restricted to TGF-β signaling. 
By inhibiting the biosynthesis of mevalonate and its metabolites, lovastatin is 
recognized to exert a number of off-target effects by disrupting the post-
translational modification of a wide variety of proteins including the Ras, Rab, 
and Rho families [90, 91]. Still, direct genetic and pharmacologic studies 
assessing the potential role of dysregulated TGF-β signaling in NF1 associated 
bone defects remain lacking. 
The complex role of TGF-β in bone remodeling 
Three distinct yet structurally similar isoforms of TGF-β (TGF-β1 to -β3) 
exist in mammals [92]. These are differentially expressed in various tissues and 
induce different biological effects. Considerable evidence suggests that TGF-β1 
(the predominant isoform in bone) plays a critical role in coordinating the 
formation, function, and cell-cell interactions of osteoblasts and osteoclasts to 
modulate bone mass and remodeling [87, 93-95]. TGF-β is secreted as a latent 
precursor, which is sequestered abundantly in the bone matrix. Following release 
from the bone matrix and proteolytic activation, TGF-β binds type II receptors 
which complex with and activate type I receptors, leading to the phosphorylation 
of Smad2 and Smad3 among other effector pathways (Figure 2). Phosphorylated 
Smad2/3 bind with Smad4 and together translocate to the nucleus to regulate the 
transcription of TGF-β target genes [96, 97]. 
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Studies across multiple laboratories suggest a complex regulatory system 
in which TGF-β induces biphasic effects on bone cells. In vitro studies reveal that 
at early stages of osteoblast differentiation, TGF-β1 increases bone formation by 
stimulating the recruitment and proliferation of osteoblast progenitors [87]. 
Consistent with these observations, TGF-β1 knockout mice exhibit reduced bone 
mineral density and bone elasticity [98, 99]. Contrastingly, at later stages, TGF-
β1 has been show to potently inhibit terminal osteoblast differentiation, 
suppressing mineralization and osteocalcin expression [100, 101]. In vivo, the 
attenuation of TGF-β signaling in osteoblasts by overexpression of a truncated, 
dominant negative TGF-β type II receptor in transgenic mice enhanced 
trabecular bone mass and resistance to fracture [102]; mice with conditional 
knockout of the TGF-β type II receptor show a similar phenotype [103]. 
Reduction of TGF-β signaling through its effector Smad3 can also promote 
anabolic bone remodeling; Smad3+/- mice show increased bone mass, matrix, 
and mechanical properties as compared to controls [95]. 
As with osteoblasts, TGF-β has also been shown to exert differential 
effects on osteoclasts. Several in vitro studies contend that TGF-β inhibits 
osteoclastogenesis both directly and indirectly by increasing the ratio of 
OPG/RANKL production by osteoblasts [104-106]. On the opposing end of the 
spectrum, however, other groups have reported increased osteoclast formation in 
cultures from spleen, bone marrow, and peripheral blood mononuclear cells 
following exposure to TGF-β [107-110]. Recently, Gingery et al. concluded that 
TGF-β coordinately activates the TAK1/MEK/AKT/NFκB and SMAD pathways to 
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promote osteoclast survival [111]. Futakuchi et al. also found that TGF-β 
increased osteoclastogenesis and bone resorptive activity in RANKL stimulated 
RAW 264.7 macrophage-like cells [112]. Yet despite conflicting in vitro data, in 
vivo data generated from transgenic mouse models consistently suggest that 
TGF-β positively regulates osteoclast differentiation and function [94, 95]. 
Although osteoclasts derived from Nf1+/- mice and the peripheral blood of human 
NF1 patients exhibit multiple gain-in-functions [69, 70], the potential contribution 
of excessive TGF-β signaling to the enhanced bone resorptive capacity of Nf1+/- 
osteoclasts remains unknown. 
TGF-β antagonism as a novel strategy in bone formation therapy 
The concept that attenuation of TGF-β signaling can produce both 
anabolic as well as anti-catabolic effects on bone is further supported by recent 
studies utilizing small molecule inhibitors of TGF-β receptors and TGF-β 
neutralizing antibodies. Mohammad and colleagues demonstrated that 
pharmacologic TGF-β blockade with SD-208, a small molecule inhibitor of TGF-β 
type I receptor (TβRI) kinase activity, increased bone mass and quality [113]. SD-
208 treated mice showed enhanced osteoblast differentiation and bone 
formation, while osteoclast formation and bone resorption were reduced [113]. 
Similar results were achieved utilizing 1D11, a neutralizing antibody directed 
against all three TGF-β isoforms [114]. 
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Figure 2. Cartoon schematic of TGF-β signaling. TGF-β binds type II 
receptors (TβRII), which complex with and activate type I receptors (TβRI), 
leading to activation of the canonical Smad pathway. The pharmacologic agent 
SD-208 blocks TGF-β signaling by inhibiting TβRI kinase activity. 
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Thesis overview 
Establishing animal models which accurately recapitulate the full spectrum 
of osseous features seen in NF1 patients is critical to improving our 
understanding of the cellular and molecular etiology of these anomalies. Here we 
describe the generation and phenotypic characterization of a novel NF1 murine 
model: Nf1flox/-;Col2.3Cre mice, which exhibits multiple osseous deficits including 
runting (short stature), low bone mass, vertebral defects, and tibial fracture non-
union as described herein. These features are closely reminiscent of those 
observed in the human disease, thus rendering the Nf1flox/-;Col2.3Cre model a 
viable platform from which to interrogate the cellular and molecular mechanisms 
underpinning the pathogenesis NF1 associated skeletal deficits. 
We have further demonstrated through a series of adoptive bone marrow 
transfer experiments, that the Nf1 haploinsufficient hematopoietic 
microenvironment is critical to the pathogenesis of bone mass deficits and tibial 
fracture non-union in Nf1flox/-;Col2.3Cre mice. However, which specific 
hematopoietic lineage(s) play a pivotal role in this process remains unclear. 
Given that Nf1 haploinsufficiency leads to Ras mediated cytokine hypersensitivity 
in multiple myeloid lineages, we reasoned that Nf1 haploinsufficiency in 
osteoclasts and their precursors within the myeloid lineage may be required for 
the genesis of the observed osseous phenotypes. 
To test this hypothesis, we generated Nf1flox/+;LysMCre mice harboring 
conditional inactivation of a single Nf1 allele in myeloid cells. Indeed 
Nf1flox/flox;Col2.3Cre mice stably reconstituted with Nf1flox/+;LysMCre 
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hematopoietic cells exhibited significant defects in tibial fracture healing as 
compared to controls reconstituted with WT bone marrow. Compared to WT BM 
cells, mice reconstituted with Nf1flox/+;LysMCre BM cells exhibited deficient 
cortical bridging and significantly reduced callus bone volume fraction (BV/TV) as 
determined by micro-computed tomography (µCT), indicating substantial deficits 
in fracture repair. Histological analysis revealed fibrous infiltrates and excessive 
osteoclast numbers within the fracture callus. 
To further dissect the stage of myeloid development at which Nf1 
haploinsufficiency is permissive of osteoclast gain-in functions, we compared the 
phenotype of Nf1flox/+;LysMCre mice to Nf1flox/+;CtskCre mice, where conditional 
inactivation of a single Nf1 allele is restricted to mature osteoclasts. While 
Nf1flox/+;LysMCre mice exhibit increased osteoclast progenitor frequency (CFU-
M), enhanced osteoclastogenesis, and accelerated bone loss following 
ovariectomy induced resorptive challenge, Nf1flox/+;CtskCre mice did not 
recapitulate these phenotypes in analogous experiments. These data provide 
direct genetic evidence that haploinsufficiency of Nf1 in myeloid progenitors, but 
not terminally differentiated OCs alone, is required to expand the pool of OC 
progenitors, thereby enabling increased bone resorption in vivo. 
Collectively, these findings suggest that the cellular mechanisms of Nf1 
osseous dysplasia are complex and may require the cooperative interaction of 
Nf1 nullizygous osteoblasts and/or progenitors, as well as Nf1 heterozygous 
osteoclasts and their myeloid precursors. On the molecular level, transforming 
growth factor-beta1 (TGF-β1) has become increasingly recognized as a master 
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regulator in the spatiotemporal coupling of osteoblast and osteoclast activity [94]. 
Dysregulated TGF-β signaling is associated with a spectrum of osseous defects 
seen in Loeys-Dietz syndrome [115-118], Marfan syndrome [119-123], and 
Camurati-Engelmann disease [124]. Intriguingly, neurofibromatosis type 1 (NF1) 
patients recapitulate many of these characteristic skeletal features; however, the 
molecular mechanisms underlying these phenotypes remain unclear. Having 
previously established that Nf1 haploinsufficient myeloid cells potentiate 
neurofibroma phenotypes through secreted TGF-β signaling [89], we reasoned 
that analogous dysregulated paracrine signaling may be integral to the 
pathogenesis of NF1 skeletal defects. 
Here, we provide genetic and pharmacologic evidence that hyperactive 
TGF-β1 signaling pivotally underpins osseous defects in Nf1flox/-;Col2.3Cre mice. 
Compared to controls, we show that serum TGF-β1 levels are five- to six- fold 
increased both in Nf1flox/-;Col2.3Cre mice and in a cohort of NF1 patients. Nf1 
deficient osteoblasts, the principal source of TGF-β1 in bone, overexpress TGF-
β1 in a gene dosage dependent fashion. Moreover, Nf1 deficient osteoblasts and 
osteoclasts are hyperresponsive to TGF-β1 stimulation, potentiating osteoclast 
bone resorptive activity while inhibiting osteoblast differentiation. These cellular 
phenotypes are further accompanied by p21-Ras dependent hyperactivation of 
the canonical TGF-β1-Smad pathway. Re-expression of the human, full-length 
neurofibromin GTPase-activating protein (GAP) related domain (NF1 GRD) in 
primary Nf1 deficient osteoblast progenitors, attenuated TGF-β1 expression 
levels and reduced Smad phosphorylation in response to TGF-β1 stimulation. As 
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an in vivo proof of principle, we demonstrate that administration of the TβRI 
kinase inhibitor, SD-208, can rescue bone mass deficits and prevent tibial 
fracture non-union in Nf1flox/-;Col2.3Cre mice. In sum, these data demonstrate a 
pivotal role for hyperactive TGF-β1 signaling in the pathogenesis of NF1 
associated osteoporosis and pseudarthrosis, thus implicating the TGF-β 
signaling pathway as a potential therapeutic target in the treatment of NF1 
osseous defects which are refractory to current therapies. 
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CHAPTER 2. MATERIALS AND METHODS 
 
Animals 
Nf1+/- mice [125] were obtained from Tyler Jacks of the Massachusetts 
Institute of Technology (Cambridge, Massachusetts, USA). Nf1flox/flox mice [126], 
provided by Dr. Luis Parada at the University of Texas Southwestern Medical 
Center, were intercrossed with Nf1+/- and 2.3kb α1 (I) collagen Cre (Col2.3Cre) 
mice [127] to selectively drive expression of Cre recombinase in the osteoblast 
lineage. Four genotypes of mice were generated from the intercross (Figure 3). 
(1) Nf1flox/flox;Col2.3Cre- mice (wild-type (WT) background); (2) Nf1flox/-;Col2.3Cre- 
mice (Nf1+/- background); (3) Nf1flox/flox;Col2.3Cre+ mice (WT background and 
Nf1-/- osteoblasts); and (4) Nf1flox/-;Col2.3Cre+ mice (Nf1+/- background and Nf1-/- 
osteoblasts) as published previously [77, 78]. 
As further validation of this model, Col2.3Cre transgenic mice were 
intercrossed with ROSA26 flox/flox reporter mice. LacZ staining was performed to 
assess Cre recombination in skeletal tissues. Abundant β-galactosidase 
expression was observed in the long bones and vertebrae of ROSA26 
flox/flox;Col2.3Cre+ mice, but was absent in ROSA26 flox/flox;Col2.3Cre- controls 
(Figure 4). Efficient deletion of neurofibromin in osteoblasts was further 
confirmed by western blot (Figure 5). 
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Figure 3. Breeding schema. Nf1+/-, Nf1flox/flox, and Col2.3Cre+ mice were 
intercrossed to yield four resulting genotypes of mice. (1) Nf1flox/flox;Col2.3Cre- 
mice (WT); (2) Nf1flox/-;Col2.3Cre- mice (Nf1+/-); (3) Nf1flox/flox;Col2.3Cre+ mice (WT 
background with Nf1-/- osteoblasts); and (4) Nf1flox/-;Col2.3Cre+ mice (Nf1+/- 
background with Nf1-/- osteoblasts). 
30 
 
Figure 4 
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Figure 4. LacZ staining was performed to assess Cre recombination in the long 
bones and vertebral spine. β-galactosidase was abundantly expressed in the 
long bones and vertebrae of ROSA26flox/flox;Col2.3Cre+ mice, but not present in 
ROSA26flox/flox;Col2.3Cre- controls. 
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Figure 5 
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Figure 5. Western blot showing the relative neurofibromin expression level in 
osteoblasts cultured from WT, Nf1flox/flox;Col2.3Cre, and Nf1flox/-;Col2.3Cre mice. 
Neurofibromin expression was undetectable in osteoblasts cultured from both 
Nf1flox/flox;Col2.3Cre and Nf1flox/-;Col2.3Cre mice, indicating that phenotypic 
differences between these strains are not attributable to differential Cre 
recombination of Nf1 in the osteoblast lineage. 
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Conditional Nf1 haploinsufficiency in myeloid progenitors and osteoclasts 
was achieved by placing Cre recombinase under the control of either the 
Lysozyme M (LysM) or Cathepsin K (Ctsk) promoter. LysMCre mice [128], 
generated by Dr. Irmgard Forster (University of Dusseldorf), and CtskCre 
mice[129], generated by Dr. R.A. Davey (University of Melbourne, Australia) 
were purchased from the Jackson Laboratory and intercrossed with Nf1flox/flox 
mice to yield Nf1flox/+;LysMCre+ and Nf1flox/+;CtskCre+ mice. Nf1flox/+;LysMCre- and 
Nf1flox/+;CtskCre- mice were used respectively as WT controls. Cre mediated 
recombination of the floxed Nf1 allele was validated by PCR and western blot 
(Figure 6A-C). Experimental animals were maintained at the Indiana University 
Laboratory Animal Research Center (LARC) in accordance with the Institutional 
Animal Care and Use Committee (IACUC) guidelines. 
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Figure 6A 
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Figure 6B 
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Figure 6C 
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Figure 6. Validation of Nf1flox/+;LysMCre and Nf1flox/+;CtskCre mouse models. (A) 
PCR genotyping was performed on tail genomic DNA from WT and 
Nf1flox/+;LysMCre mice as shown. Bands representing the WT, Nf1-floxed, and 
LysMCre alleles are labeled accordingly. The Cre recombination band, labeled 
rCre, demonstrates efficient Cre mediated excision of the floxed Nf1 allele. (B) 
Neurofibromin expression levels were detected by western blot in macrophages 
cultured from WT and Nf1flox/+;LysMCre mice. (C) PCR genotyping of WT and 
Nf1flox/+;CtskCre mice was performed on tail genomic DNA. Bands demonstrating 
the presence or absence of CtskCre are shown. 
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Isolation of bone marrow 
Bone marrow was flushed from the femur, tibia, and iliac crest in a 5 mL 
volume of Alpha-Minimum Essential Medium (α-MEM, Gibco/Invitrogen), 
supplemented with 10% fetal bovine serum (FBS) using a 1.5 inch 23-guage 
needle. Low density bone marrow mononuclear cells (BMMNCs) were isolated 
by density gradient centrifugation for 30 min at 1750 rpm (gh-3.8 rotor, Beckman 
Coulter) on a 3.5 mL volume of Histopaque (Sigma). The buffy coat layer was 
collected and washed with α-MEM or other media prior to further assays. 
 
Osteoclast culture 
Murine osteoclasts 
5 x104 BMMNCs from Nf1+/- and WT mice were cultured in 96-well plates 
in α-MEM supplemented with 10% FBS in the presence of murine recombinant 
RANKL (20 ng/mL; PeproTech), murine recombinant M-CSF (30 ng/mL; 
PeproTech), and in some instances, TGF-β1 (1 ng/mL; R&D Systems). After 
three days, the medium was changed to M-CSF (30 ng/mL), RANKL (60 ng/mL), 
and for certain experiments, TGF-β1 (1 ng/mL) for an additional three days of 
culture. To identify osteoclasts at the end of culture, adherent cells were fixed 
with and stained for tartrate resistant acid phosphatase (TRACP) using a 
commercially available kit (Sigma) according to the manufacturer’s instructions. 
Images were acquired on a Nikon TE2000-S microscope using a QImaging 
camera and QCapture Pro software. Multinucleated, TRACP positive staining 
cells containing more than three nuclei were scored as mature osteoclasts. 
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Number of nuclei per osteoclast, mean osteoclast size, and TRACP positive 
multinucleated osteoclast area per high power field (HPF) were scored 
quantitatively using Image J software. 
Human osteoclasts 
 Peripheral blood mononuclear cells (MNCs) were separated from 
heparinized peripheral blood by Histopaque (Sigma) centrifugation. MNCs were 
plated at a density of 5 x 104 MNCs per well in 96-well plates and cultured in α-
MEM supplemented with 10% FBS, human recombinant RANKL (50 ng/mL; 
PeproTech), and human recombinant M-CSF (30 ng/mL; PeproTech) for seven 
days with media replacement on day four as previously described [71]. Adherent 
cells were fixed in 10% formaldehyde in PBS, treated with ethanol–acetone 
(50:50), and stained for TRACP (Sigma). Images were acquired and analyzed in 
the same manner described above for murine osteoclast cultures. 
 
Osteoclast “pit” formation assays 
Bone marrow mononuclear cells were seeded on dentine slices (ALPCO 
Diagnostic, Windham, NH) and cultured in the presence of M-CSF and RANK-L 
at 37°C, 5% CO2. Following seven days culture, dentine slices were rinsed with 
PBS and immersed overnight in 1 M ammonium hydroxide. After staining with a 
1% crystal violet solution, the number and area of resorptive “pits” were 
quantified using NIH Image J Software on low-power fields (100x magnification). 
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Mesenchymal stem cell culture 
BMMNCs flushed from the femora, tibiae, and iliac crests were suspended 
in 10 mL MesenCult® Mesenchymal Stem Cell (MSC) Basal Medium (Mouse) 
plus MSC Stimulatory Supplements (Stem Cell Technologies) and plated in a 10-
cm tissue culture dish at 37°C, 5% CO2 for continuous culture as described 
previously [73]. Once the cultures were 80–90% confluent, adherent cells were 
trypsinized and replated. MSCs at passage five to passage 10 were used for 
experiments. 
 
Osteoblast culture 
Osteoblast differentiation from MSCs 
5 x 104 MSCs were plated in 12-well tissue culture dishes and 
supplemented with osteogenic differentiation medium (MesenCult® MSC Basal 
Medium plus MSC Stimulatory Supplements, 10-8 M dexamethasone, 5 mg/mL 
ascorbic acid 2-phosphate and 10 mM β-glycerophosphate). The medium was 
changed every other day for one week of continuous culture as described 
previously [73]. Some MSCs were also supplemented with TGF-β1 (1 ng/mL) 
and SD-208 (1 µM) (Tocris Bioscience). Alkaline phosphatase (ALP) activity was 
subsequently assessed using an ALP staining kit (Sigma) according to the 
manufacturer’s instructions. Photomicrographs of the stained cells were acquired 
with a Nikon TE2000-S microscope. ALP positive staining was quantified using 
Image J software. 
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Vertebral osteoblast cultures 
Osteoblast-like cells were cultured from vertebrae as previously reported 
with minor modifications [130, 131]. Briefly, one-month-old mice were sacrificed 
and vertebrae were isolated by removing the surrounding muscle and connective 
tissue. Individual vertebrae (L1–L5) were collected and minced. Marrow cells 
were harvested by digestion of the minced tissue in a solution of type III 
collagenase (0.1 mg/mL) and 2.5% trypsin, while shaking in a hot water bath at 
37°C for 40 min. The reaction was stopped by addition of 10 volumes of 
Dulbecco's Modified Eagle Media (DMEM; Gibco/Invitrogen) supplemented with 
10% fetal bovine serum (FBS). The cells were then washed once with DMEM, 
and aggregates were removed from the cell suspension by sieving through a 70 
μm strainer. Cell number was determined by counting trypan blue negative cells. 
To examine the frequency of osteoblast progenitors in the marrow of 
Nf1flox/-;Col2.3Cre lumbar vertebrae, colony forming units of osteoblasts (CFU-
OBL) were assessed following ALP staining as previously described [73]. In brief, 
mononuclear cells from lumbar vertebrae were cultured at 2×106/mL in 
osteogenic differentiation medium (MesenCult® MSC Basal Medium plus MSC 
Stimulatory Supplements with 10-8 mol/L dexamethasone, 5 μg/mL ascorbic acid 
2-phosphate, and 10 mmol/L β-glycerophosphate). After two weeks of culture, 
cells were washed with PBS and stained with 2% Alizarin Red S solution (pH = 
4.2) for one hour. The cells were then washed with distilled water and incubated 
with 500 μL of 1% hydrochloric acid in 70% ethanol and shaken on a plate rotator 
for 30 min. The extracted supernatant was collected and the optical density was 
43 
measured at a wavelength of 450 nm. For each sample, measurements were 
performed in triplicate. 
Von Kossa staining was also used to evaluate the osteogenic 
differentiation of marrow cells from the vertebrae. After four weeks culture in 
osteoblast differentiation media in 6-well tissue culture plates, the cells were fixed 
with 10% neutral formalin. Freshly prepared 5% silver nitrate (2 mL) was added 
to each well, and then incubated under UV light for 60 min. The dishes were then 
rinsed with distilled water and fixed with 5% sodium thiosulfate for 2 min. The 
wells were photographed using a phase-contrast microscope, and the number of 
mineralized bone nodules was recorded. 
 
Quantitative real-time PCR 
Tgfb1 gene expression in WT and Nf1 deficient MSCs was determined 
using quantitative real-time PCR. Primers used for Tgfb1 were 
CAGTGGCTGAACCAAGGA (forward) and AGCAGTGAGCGCTGAATCG 
(reverse) and for Gapdh TGCACCACCAACTGCTTAG (forward) and 
GGATGCAGGGATGATGTTC (reverse). Total RNA was extracted using an 
RNeasy Plus mini kit (Qiagen). Reverse transcription was performed, and real-
time PCR was carried out on an ABI 7500 system with SYBR® Green reagents 
(Applied Biosystems). Relative Tgfb1 gene expression levels were determined 
with respect to the Gapdh control using the ∆CT  method [132]. 
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Serum TGF-β1 measurement 
250 µL of peripheral blood was collected by tail vein bleeding into EDTA-
coated tubes (Beckton Dickinson). Serum was obtained following centrifugation 
at 3000 rpm in a microcentrifuge for 10 min. Total serum TGF-β1 levels were 
determined using a mouse TGF-β1 DuoSet ELISA Development kit (R&D 
systems). Since the assay is designed to detect only active TGF-β1, total TGF-β1 
levels were measured by acid activation of latent TGF-β1 with 1 N HCL for 10 
min, followed by neutralization with a 1.2 N NaOH/0.5 M HEPES solution per the 
manufacturer’s protocol. 
 
Western blotting 
Following stimulation with TGF-β1 and/or various inhibitors, cells were 
lysed in a RIPA lysis buffer containing inhibitors for proteases and phosphatases. 
Isolated proteins were fractionated using NuPAGE 4-12% Bis-Tris Gels 
(Invitrogen) and electro-transferred to PVDF membranes. Callus proteins were 
harvested 14 days after tibial fracture using a mortar and pestle to grind the 
callus in proteolysis buffer. Immunoblots were carried out using antibodies 
specific to p-Smad2 (Cell Signaling), total Smad2 (Cell Signaling), active TGF-β1 
(R&D Systems), latent (LAP)TGF-β1 (R&D Systems), and β-actin (Sigma). After 
incubation with anti-rabbit IgG or anti-mouse IgG (GE Healthcare) antibodies 
conjugated with HRP, signals were detected using ECL chemiluminescence 
substrate (Amersham). Densitometry was performed using Image J software. 
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Smad dual-luciferase reporter assays 
Osteoprogenitors were transfected with Smad reporter, negative, and 
positive control dual-luciferase constructs (Cignal Reporter Assay, Qiagen) [133]. 
The Smad reporter construct contains a mixture of an inducible Smad responsive 
firefly luciferase reporter and a constitutively expressed Renilla construct in a 
40:1 ratio. The Renilla construct constitutively expresses the Renilla luciferase 
reporter gene under the control of a CMV promoter element and functions as an 
internal control for normalizing transfection efficiencies. The negative control 
construct contains a mixture of non-inducible firefly luciferase reporter together 
with the constitutively expressed Renilla construct in a 40:1 ratio. The positive 
control construct contains a mixture of a constitutively expressing GFP, firefly 
luciferase, and Renilla luciferase constructs in a 40:1:1: ratio. Transfection was 
performed by incubating constructs in a 3:1 FuGENE® HD Transfection 
Reagent:DNA ratio according to the manufacturer’s instructions (Promega). 24 
hours following transfection, the culture medium was changed and supplemented 
with either recombinant active TGF-β1 (1 ng/mL) or 100 times the concentration 
of latent, LAP-TGF-β1 (100 ng/mL) for an additional 18 hours. Firefly and Renilla 
luciferase activities were measured on a 96-well microtiter plate luminometer 
(Thermo Labsystems) with LAR II and Stop&Glo reagents from the dual 
luciferase assay kit (Promega). 
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Retroviral expression of NF1 GRD 
Recombinant retrovirus constructs were used to re-express the human, 
full-length NF1 GTPase activation (GAP) related domain (NF1 GRD) in Nf1 
deficient MSCs under the transcriptional control of the murine stem cell virus 
(MSCV) promoter as described previously [73, 134]. A puromycin resistance 
gene, pac, is also placed under the control of the phosphoglycerate kinase (PGK) 
promoter as a selectable marker. 72 hours after transduction, puromycin (4 
μg/mL) was used for selection.  
 
Gelatin zymography 
Gelatinolytic activities of murine myeloid cell conditioned media and 
human serum samples were assessed using sodium dodecyl sulfate (SDS) – 
polyacrylamide gel electrophoresis under non-reducing conditions as described 
previously [135]. Myeloid cell conditioned media (15 µL) was mixed with 5 µL of 
loading buffer (0.16 M Tris-HCl, 50% glycerol, 8% SDS, and 0.08% bromophenol 
blue) and loaded onto a 10% polyacrylamide gel copolymerized with 2 mg/mL 
gelatin (Sigma). Electrophoresis was performed at 120 V for 2-3 hours at 4°C. 
Gels were washed three times for 20 minutes each by immersion in 2.5% Triton 
X-100 (Sigma) with gentle shaking to remove residual SDS. Renaturation of the 
electrophoresed enzymes was achieved by incubation in zymography buffer 
(0.15 M NaCl, 5 mM CaCl2, 0.05% NaN3, 50 mM Tris-HCl, pH 7.5) for 48 hours at 
room temperature. Zones of lytic activity were revealed by staining with 0.05% 
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Coomassie brilliant blue G-250 (Sigma) in 2.5:1:7 ethanol-acetic acid-water 
followed by destaining with 2:1:7 isopropanol-acetic acid-water. 
 
Flow cytometry 
Marrow cells were incubated for 45 min at 4°C with saturating 
concentrations of anti-mouse antibodies in 100 µL 3% FBS/0.09% NaN3 in PBS 
with 0.25 µg anti-mouse CD16/CD32 (“Fc Block”). For the myeloid progenitor 
analysis, the following antibodies from BD Biosciences were used: FITC-
conjugated anti-lineage markers (CD3, CD4, CD8, B220, Mac1, Gr1, Ter119), 
anti-CD16/32-PE, anti-CD34-PacificBlue, anti-Sca1-APC-Cy7, and anti-c-Kit-
PerCP-Cy5.5. For the mature lineage analysis, the following antibodies from BD 
Biosciences were used: anti-CD3-FITC, anti-CD8-PacBlue, anti-B220-V500, anti-
Mac1-PE, anti-Gr1-PECy7, anti-CD4-APC-Cy7, anti-CD45.2-PerCP-Cy5.5. Cells 
were analyzed on an LSR II 407 flow cytometer, and single color compensation 
controls were acquired using polystyrene microbeads (BD Biosciences). All post-
acquisition analyses were performed with FlowJo 7.6.3 software (TreeStar) with 
gating parameters determined by fluorescence minus-one controls. The following 
gating definitions were used: granulocyte-monocyte progenitors (GMPs): Lin–
Sca1–c-Kit+CD34+FcγRII/ II+; myeloid cells: CD3-B220-; and monocytes: CD3-
B220-Gr1-Mac1+ as described elsewhere [136]. 
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Bone marrow transplantation 
3 x 106 syngeneic WT or Nf1flox/+;LysMCre bone marrow cells were 
injected intravenously into the tail vein of lethally irradiated (1100 cGy, split dose) 
Nf1flox/flox;Col2.3Cre recipient mice [84]. After waiting four months to allow stable 
engraftment of the donor hematopoietic cells, tibial fractures were induced as 
described below. 
 
Ovariectomy surgery 
12-week old mice underwent either ovariectomy or sham surgery. Mice 
were anesthetized using a mixture of ketamine (150 mg/kg) and xylazine (10 
mg/kg) administered IP. A 2-cm midline dorsal skin incision was made, followed 
by incision of the peritoneal cavity to identify and excise the ovaries. pDEXA 
scans were acquired prior to surgery and again six weeks post-operatively to 
assess the percent change in BMD as described below. At the experimental 
endpoint of six weeks, the long-bones were excised for post-mortem analysis. 
Uterine weights of ovariectomized and sham operated mice were compared to 
validate the surgical method (Figure 7A, B). 
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Figure 7A 
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Figure 7B 
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Figure 7. Uterine weights of ovariectomized (OVX) and sham operated mice 
were compared to validate the surgical method. (A) Representative 
photographs illustrate the uterine size of sham versus OVX mice. (B) The uterine 
weight (mg) was measured on an analytic balance as shown in the bar graph 
above. n = 20 per group. ***P < 0.001, comparing the mean uterine weight of 
OVX mice to sham operated controls. 
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Tibial fracture 
Open tibial fractures were induced by a three-point method in 12-week old 
Nf1flox/-;Col2.3Cre mice under ketamine anesthesia as described previously [78, 
137]. Prior to fracture, an intramedullary stabilizing rod (27-G needle) was 
inserted into the tibia to permit load-bearing. A 200-gram weight was dropped 
from a height of 30-cm to fracture the tibia. Proper fracture position between the 
middle to distal 1/3 of the tibia below the fibular junction was confirmed by x-ray 
(pixRay-100, Bioptics). Weekly radiographs were acquired to monitor fracture 
healing. Mice were euthanized with carbon dioxide at the experimental endpoint 
of four weeks. The long bones were harvested for further evaluation by μCT and 
histology as described below. 
 
TβRI inhibitor treatment 
The TβRI kinase inhibitor, SD-208, was reconstituted in a vehicle solution 
of 1% methylcellulose in sterile water. SD-208 was administered by gavage at a 
dose of 60 mg/kg/day. Some cohorts received the vehicle treatment (1% 
methylcellulose) as a control. Treatments were delivered once daily, beginning at 
the time of tibial fracture surgery for a duration of four weeks. For ovariectomy 
studies, SD-208 or vehicle was administered daily for six weeks. 
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Biomechanical testing 
Vertebral compression tests 
To evaluate the structural integrity of L5 vertebrae, biomechanical testing 
was conducted utilizing an R Series PC Controlled Test System: R 1.4.2 
(TestResources Inc.). L5 vertebral bodies were isolated by removing the 
surrounding soft tissue and the adjacent intervertebral discs to expose the cranial 
and caudal bone surfaces. After equilibration to room temperature, L5 vertebral 
bodies were subjected to mechanical testing in compression at a rate of 20 
mm/min. Peak load was defined as the maximum load that the specimen can 
withstand before fracturing. The cross sectional area of each vertebral body was 
measured in the medial and lateral (transverse) planes. Peak stress was 
calculated by the equation: peak stress = peak load/vertebral cross sectional 
area. 
Three-point bending 
Following euthanasia, the left tibia was dissected to remove the 
surrounding soft tissue, wrapped in saline-soaked gauze, and stored at -20°C. At 
the time of testing, all samples were equilibrated to RT in a saline bath. Tibias 
were positioned with the posterior side facing upwards across the two lower 
supports of an Electroforce 3200 three-point bending apparatus (Bose). The 
bones were loaded to failure under monotonic compression at a crosshead 
speed of 0.2 mms/s. Force-displacement measurements were acquired at 0.005 
s intervals at a force resolution of 0.01 N. Ultimate force (N), yield force (N), 
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stiffness (N/mm), energy to failure (mJ), failure (breaking) force (N), and energy 
to yield (mJ) were computed from the force versus displacement curves. 
 
X-ray 
X-rays were acquired using a piXarray 100 DSR System (Bioptics). Whole 
spine anterior–posterior radiographs were taken. The height (mm) of the L5 
vertebral body was measured between the cranial and caudal ends. In other 
experiments, lateral radiographs of fractured tibiae were obtained weekly under 
ketamine anesthesia. Fracture healing was monitored for a duration of four 
weeks until the experimental endpoint was reached. 
 
Peripheral dual-energy X-ray absorptiometry (pDEXA) 
BMD was measured using a PIXImus mouse densitometer (GE Lunar II, 
Faxitron Corp., Wheeling, IL). The mice were placed in the prone position on a 
specimen tray and scanned. The skull was excluded from total body scans. 
Regions of interest (ROI) included the lumbar spine (20 x 50 pixels) and distal 
femur immediately proximal to the growth plate (12 x 12 pixels). For certain 
experiments, the percent change in BMD was determined by comparing a 
baseline scan, acquired prior to the initiation of ovariectomy surgery or drug 
treatment, with an endpoint scan acquired prior to euthanasia. 
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Peripheral quantitative computed tomography (pQCT) 
The whole axial spine was placed in the gantry of a XCT Research SA+ 
pQCT scanner (Stratec Medizintechnik GmbH, Pforzheim, Germany) with 
Software Version 5.50. A voxel size of 70 μm was used for analysis. A scout view 
was obtained and the anatomical reference line was positioned at the midpoint of 
the rostral/caudal margin of the L5 pedicle. Individual slices were obtained from 
each vertebra. The centrum of the vertebra was selected as the ROI. Volumetric 
bone mineral density (vBMD; mg/cm3) of the cortical and trabecular bone was 
measured. The ratio of spinal canal area/vertebral body area was derived by 
measuring the area of the L5 vertebral body and the spinal intervertebral canal 
from the pQCT images. 
 
Micro-computed tomography (µCT) 
Formalin fixed femora were placed in the gantry of a micro-computed 
tomographer (VivaCT 40, SCANCO Medical). Images were acquired at a voxel 
size of 10.5 µm. The voxel of interest (VOI) comprised 100 transverse CT slices 
beginning 250 µm away from the femoral growth plate and extending proximally. 
Fractional bone volume (BV/TV, fraction) and microarchitectural properties of 
trabecular reconstructions, including trabecular thickness (Tb.Th., mm), 
trabecular number (Tb.N., mm-1), trabecular spacing (Tb.Sp., mm), and 
connectivity density (Conn.D., mm-3) were calculated using standard algorithms. 
For quantitative evaluation of tibial fracture calluses, contouring was performed 
for 100 transverse CT slices extending in both directions from the fracture 
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midline. Callus fractional bone volume (BV/TV) and volumetric bone mineral 
density (vBMD) were measured within the callus, excluding the cortical bone 
comprising the original tibial shaft. 
 
Histology 
Femur 
Tissues were fixed in 10% formalin for 48 hours, demineralized for two 
weeks in 10% EDTA, and embedded in paraffin. 3.5 µm thick longitudinal 
sections were cut using a rotary microtome (Leica). Trabecular BV/TV of the 
secondary spongiosa and osteoblast numbers (N.Ob/BS) normalized to the bone 
surface were quantified on H&E stained sections of the distal femur at 200x 
magnification using BIOQUANT OSTEO v11.2 software (BIOQUANT Image 
Analysis Corporation). In a similar fashion, osteoclast numbers normalized to the 
bone surface (N.Oc/BS) were quantified on TRACP stained sections at 200x 
magnification. 
 
Lumbar vertebrae 
Lumbar vertebrae were harvested and fixed in 4% formaldehyde at RT. 
The vertebrae were then decalcified in 10% EDTA, 4% formaldehyde for four 
days. The tissues were then dehydrated in graded alcohols and embedded in 
paraffin. 5-μm thick longitudinal sections of L5 were obtained and processed for 
TRACP staining and MacNeal staining. N.Oc/BS and N.Ob/BS were quantified 
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by manual cell counting at 200x magnification on TRACP and MacNeal-stained 
sections, respectively. 
 
Immunohistochemistry 
For p-Smad2 immunohistochemical staining, sections were incubated in 
DeCal Retrieval Solution (Biogenex Laboratories, San Ramon, CA) for 30 min at 
RT. Primary antibody to p-Smad2 (Cell Signaling, diluted 1:100) was applied 
overnight at 4°C. Vectastain ABC kit containing biotinylated secondary antibody 
(diluted 1:2000) and 3,3’-diaminobenzidine (DAB) substrate kit (Vector 
Laboratories) were used for detection. Quantification of p-Smad2 staining in 
fracture calluses was performed with Aperio ImageScope v11.1.2.760 software 
using the Positive Pixel Count v9 algorithm under default settings. 
 
Dynamic histomorphometry 
Two doses of the fluorochrome label calcein (30 mg/kg) were 
administered by intraperitoneal injection 11 and three days prior to euthanasia. 
Femurs were fixed in 10% neutral-buffered formalin for 48 hours, dehydrated in 
graded ethanols, and embedded without decalcification in methylmethacrylate. 6-
µm thick sections were analyzed at 100x magnification on four independent fields 
beginning 100 µm distal to the growth plate and excluding cortical bone. The 
bone surface (BS), single labeled surface (sLS), double label surface (dLS), and 
interlabel width (Ir.L.Wi) were determined by manually tracing the perimeter of 
interest in BIOQUANT OSTEO v11.2 software (BIOQUANT Image Analysis 
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Corporation). The mineralizing surface (MS/BS; %), mineral apposition rate 
(MAR, µm/day), and bone formation rate (BFR; µm3/µm2/year) were derived 
using standard formulas. 
 
Statistical analysis 
Differences between experimental groups were interrogated using the 
Student’s t-test or either one- or two-factor analysis of variance (ANOVA) 
statistical tests as appropriate. In the instances where the ANOVA was 
significant, post-hoc testing was performed between individual groups using the 
Newman-Keuls multiple comparison test. An alpha level of 5% was set as the 
type I error rate for all studies, with p values < 0.05 required to reject the null-
hypothesis. 
59 
CHAPTER 3. MODELING NF1 SKELETAL DEFECTS IN THE MOUSE 
 
Introduction 
The development of effective targeted therapies for the treatment of NF1 
associated skeletal manifestations has been hampered by the lack of appropriate 
animal models which accurately recapitulate the cardinal features of NF1 
osseous disease. As described in Chapter 1, genetic studies in Nf1+/- and Nf1OB-/- 
(harboring Nf1 nullizygous osteoblasts) mice have implicated Nf1 deficient 
osteoblasts and/or their progenitors as critical mediators in the recalcitrant bone 
repair process [76, 79, 138]. These models are limited, however, in that they do 
not spontaneously recapitulate many of the hallmark skeletal manifestations of 
NF1 patients including osteoporosis, spinal deformities, and pseudarthrosis 
which cumulatively affect up to 70 percent of the NF1 patient population. Here, 
we demonstrate that Nf1flox/-;Col2.3Cre mice, harboring Nf1 nullizygous 
osteoblasts on a systemic Nf1+/- background, exhibit multiple osseous features 
that are closely reminiscent of those seen in the human disease, including bone 
mass deficits (osteoporosis), spinal deformities, and tibial fracture non-union 
(pseudarthrosis). This chapter will characterize the various skeletal phenotypes 
observed in the Nf1flox/-;Col2.3Cre mouse model, correlating these findings with 
the clinical features of human patients with NF1. 
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Bone mass deficits (osteoporosis) in Nf1flox/-;Col2.3Cre mice 
 
Reduced BMD, cortical, and trabecular bone mass in the lumbar spine of Nf1flox/-
;Col2.3Cre mice 
Kuorilehto and colleagues previously documented that the lowest local 
BMD values in NF1 patients tended to be clustered to the load-carrying 
anatomical regions including the spine and lower limbs [23]. Within the spine, the 
lumbar region contains the primary load-bearing vertebrae, L1-L5. Recent clinical 
reports have confirmed that reduced BMD in the lumbar spine is a prominent 
feature of NF1 patients with bone involvement [25], and moreover, tends to 
correlate with the severity of scoliosis in such patients [30]. Here, we show that 
Nf1flox/-;Col2.3Cre mice (harboring Nf1 nullizygous osteoblasts on a Nf1+/- 
background) exhibit a phenotype which is analogous to the human disease. 
When we used pDEXA to compare the BMD of the lumbar spine (L1-L5) between 
Nf1flox/-;Col2.3Cre mice and various controls, we observed a significant reduction 
in L1-L5 BMD within the Nf1flox/-;Col2.3Cre mice versus controls (Figure 8A, B). In 
contrast, we observed no significant differences when we compared the BMD of 
the whole axial spine in Nf1flox/-;Col2.3Cre mice versus controls (Figure 8C). 
Consistent with these findings, clinical studies which report reduced BMD in site-
specific regions, such as the spine or femur of NF1 patients, often do not observe 
statistically significant differences when comparing total body BMD between NF1 
patients and healthy age/sex matched controls [25]. 
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To further dissect whether reductions in L1-L5 BMD in Nf1flox/-;Col2.3Cre 
mice were primarily due to loss of cortical or trabecular bone, we analyzed the L5 
vertebral bodies of Nf1flox/-;Col2.3Cre mice by peripheral quantitative computed 
tomography (pQCT) and compared the results to WT controls (Figure 9A). 
Cortical volumetric BMD (vBMD) (Figure 9B), cortical bone area (Figure 9C), and 
trabecular vBMD (Figure 9D) were significantly reduced in the L5 vertebrae of 
Nf1flox/-;Col2.3Cre mice. These data imply that reductions in L1-L5 BMD in Nf1flox/-
;Col2.3Cre mice are likely due to deficiencies in both the cortical and trabecular 
bone compartments. 
62 
 
 Figure 8A 
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Figure 8. Reduced bone mineral density (BMD) in the L1–L5 vertebrae of 
Nf1flox/-;Col2.3Cre mice. (A) Representative pDEXA scans. The calvarium was 
excluded from the measurement of total axial BMD. The region of interest 
enclosed by the red rectangle includes the L1–L5 vertebrae. (B) L1-L5 BMD 
(g/cm2) was quantified by pDEXA as shown. Data represent the mean ± SEM of 
nine mice in each genotype group. *P ˂ 0.05 for Nf1flox/-;Col2.3Cre mice vs. WT 
controls as determined by ANOVA and multiple-comparison post-hoc t-tests. (C) 
Total axial BMD was quantified by pDEXA and revealed no-significant 
differences between genotypes. 
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Figure 9A 
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Figure 9. Reduced cortical and trabecular bone mass in the L5 vertebrae of 
Nf1flox/-;Col2.3Cre mice. (A) Representative pQCT cross sections from L5 of four 
genotypes of mice. The relative intensity of bone is shown in the bottom panel. 
(B) Cortical vBMD of L5 was assessed at the midpoint between the rostral/caudal 
margins of the pedicle in four different genotypes of mice as shown. Data 
represent mean ± SEM of 9–10 mice per genotype. *P ˂ 0.05 Nf1flox/flox;Col2.3Cre 
vs. WT. ** P ˂ 0.001 Nf1flox/-;Col2.3Cre vs. WT. (C). The cortical bone area in the 
L5 vertebral body was compared between the four groups of mice. Data 
represent mean ± SEM of 9–10 mice per genotype. *P ˂ 0.01 Nf1flox/flox;Col2.3Cre 
vs. WT. **P ˂ 0.01 Nf1flox/-;Col2.3Cre vs. WT. (D) Trabecular vBMD within the L5 
vertebral body was compared between the four genotypes of mice. Data 
represent mean ± SEM of 9–10 mice per group. **P ˂ 0.01 Nf1flox/flox;Col2.3Cre 
vs. WT. *P ˂ 0.05 Nf1flox/-;Col2.3Cre vs. WT. 
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Reduced femoral BMD and trabecular bone mass in Nf1flox/-;Col2.3Cre mice 
The lower extremities are another load-bearing anatomical region where 
BMD is frequently compromised in the NF1 patient population [23]. We observed 
significant reductions in femoral BMD (Figure 10A) and trabecular bone volume 
fraction (BV/TV) (Figure 10B) in Nf1flox/-;Col2.3Cre mice as compared to controls. 
Corroborating these results, analogous reductions in bone mass were also 
observed in Nf1flox/-;PeriCre mice, in which a 3.9kb fragment of the Periostin 
promoter mediates Cre expression in mesenchymal stem cells (MSCs) and 
osteoblast precursors [78]. In sum, these studies validate that Nf1flox/-;Col2.3Cre 
mice develop bone mass deficits with an anatomical specificity that is analogous 
to human NF1 patients with osteoporosis. 
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Figure 10. Nf1flox/-;Col2.3Cre mice have reduced BMD and trabecular bone 
mass in the distal femur. (A) BMD was measured by pDEXA scans acquired at 
eight weeks of age. n = 10-12 mice per group. *P < 0.05 as compared to WT. (B, 
Top panel) Representative µCT reconstructions of the distal femur in longitudinal 
cross-section acquired at four months of age are shown. (Bottom panel) Femoral 
bone volume fraction (BV/TV) was quantified by µCT. n = 5 mice per group. *P < 
0.05, **P < 0.01 as compared to WT. 
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Impaired biomechanical integrity of Nf1flox/-;Col2.3Cre vertebrae and tibiae  
Recent studies have demonstrated the clinical ramifications of osteopenia 
and osteoporosis within the NF1 patient population in terms of increased fracture 
risk. NF1 patients were found to exhibit a markedly increased incidence of 
fracture and pathological fracture (occurring with minimal trauma) as compared 
to matched, healthy controls [27, 44]. We therefore sought to ascertain whether 
the bone mass reductions observed in Nf1flox/-;Col2.3Cre mice were 
accompanied by similar deficiencies in bone strength. We began by evaluating 
the load bearing capacity of L5 in mechanical compression. Peak load to failure 
in the L5 vertebrae of Nf1+/-, Nf1flox/flox;Col2.3Cre, and Nf1flox/-;Col2.3Cre mice was 
significantly diminished in comparison to WT mice (Figure 11, top panel). Both 
peak load and peak stress to failure (Figure 11, bottom panel) were lowest in 
Nf1flox/-;Col2.3Cre mice as compared to the other experimental genotypes, 
although these properties were also compromised to a lesser extent in L5 
vertebrae from both Nf1+/- and Nf1flox/flox;Col2.3Cre. These data are consistent 
with our previous observations that the most profound reductions in L5 BMD 
occurred in Nf1flox/-;Col2.3Cre mice as compared to the other mouse genotypes. 
Whole tibiae from Nf1flox/-;Col2.3Cre mice exhibited similar deficiencies in three- 
point bending, showing significant reductions in multiple mechanical indices 
including yield force (N), energy to yield (mJ), ultimate force (N), failure 
(breaking) force (N), and stiffness (N/mm) (Figure 12). 
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Figure 11. Quantitative evaluation of L5 vertebral peak load. (Top) The peak 
load to failure (N) in L5 vertebra was compared between four genotypes. *P ˂ 
0.01 for comparing Nf1+/- or Nf1flox/flox;Col2.3Cre mice with WT controls. **P ˂ 
0.001 for comparing Nf1flox/-;Col2.3Cre mice with WT mice. (Bottom) The peak 
stress (Kpa) in L5 vertebrae was measured for each genotype. *P ˂ 0.01 for 
comparing Nf1+/- or Nf1flox/flox;Col2.3Cre mice with WT controls. **P ˂ 0.001 for 
comparing Nf1flox/-;Col2.3Cre mice with WT mice. 
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Figure 12. Reduced fracture toughness in tibias of Nf1flox/-;Col2.3Cre mice. 
The mechanical integrity of tibias from WT and Nf1flox/-;Col2.3Cre mice were 
tested under three-point bending. Significant reductions in yield force (N), energy 
to yield (mJ), ultimate force (N), failure (breaking) force (N), and stiffness (N/mm) 
are shown in the bar graphs above. n = 5-7. *P < 0.05, **P < 0.01 as compared 
to WT. 
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Impaired bone remodeling in Nf1flox/-;Col2.3Cre L5 vertebrae 
Bone remodeling is a constitutive process where mature bone tissue is 
resorbed by osteoclasts and replaced with new bone matrix by osteoblasts. 
Uncoupling of this dynamic process can result in metabolic bone diseases, such 
as osteoporosis, where the resorptive capacity of osteoclasts outstrips the rate at 
which osteoblasts generate new bone matrix. We therefore tested whether 
dysregulated bone remodeling may be associated with the low bone mass 
phenotype of Nf1flox/-;Col2.3Cre mice. The bone remodeling process was 
monitored in vivo by intraperitoneal injection of two fluorochromes, calcein 
(green) and alizarin (red), administered eight and three days prior to euthanasia, 
respectively. Representative photomicrographs illustrate a markedly reduced 
incorporation of the calcein and alizarin labels into the trabecular bone surface of 
L5 Nf1flox/-;Col2.3Cre vertebrae as compared to WT controls (Figure 13A). 
Statistically significant reductions in the active bone-forming surface, or 
mineralizing surface (MS/BS, %), and the mineral apposition rate (MAR, µm/day), 
a measure of the rate of radial expansion of new bone, were observed in the 
Nf1flox/-;Col2.3Cre L5 vertebrae versus controls. Moreover, the bone formation 
rate (BFR, µm3/µm2/year), an overall measure of bone formation that combines 
MS/BS and MAR, was dramatically reduced in Nf1flox/-;Col2.3Cre mice as 
compared to WT. Collectively, these data suggest an uncoupling of the bone 
remodeling process in the Nf1flox/-;Col2.3Cre mice, in which defective Nf1 
nullizygous osteoblasts are unable to regenerate and mineralize new bone matrix 
as it is progressively degraded by hyper-resorptive Nf1+/- osteoclasts. 
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Figure 13. Defective bone remodeling in L5 vertebrae of Nf1flox/-;Col2.3Cre 
mice. (A) Representative photomicrographs show calcein and alizarin labeling of 
L5 vertebrae at 200x magnification (B) The mineral apposition rate (MAR, 
µm/day) was calculated as shown. n = 5. *P < 0.05, **P < 0.01 as compared to 
WT. (C) The bone formation rate (BFR, µm3/µm2/year) was quantified as shown. 
n = 5. *P < 0.05, **P < 0.01 as compared to WT. 
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Altered osteoclast and osteoblast numbers in Nf1flox/-;Col2.3Cre mice 
Osteoclasts and osteoblasts are the two major cell lineages responsible 
for maintaining skeletal homeostasis. Imbalances in the differentiation and/or 
activity of these cell types can lead to pathological alterations in bone mass. As 
quadrupeds, mice bear mechanical loading with the upper facet process of their 
vertebrae. To determine whether the number or morphology of these lineages 
might be altered in Nf1flox/-;Col2.3Cre mice, we quantified osteoclast and 
osteoblast numbers within histological sections of the upper L5 facet process. 
Here, we show that osteoclast numbers per mm of bone surface were 
significantly increased in the upper facet processes of Nf1+/- and Nf1flox/-
;Col2.3Cre mice as compared WT and Nf1flox/flox;Col2.3Cre mice (Figure 14A). In 
addition, significantly reduced osteoblast numbers per mm of bone surface were 
observed in the upper L5 facet process of Nf1flox/-;Col2.3Cre mice, even as 
compared to Nf1+/- and Nf1flox/flox;Col2.3Cre mice which exhibited more mild 
reductions in osteoblast counts (Figure 14B). These histological changes are 
commensurate with BMD reductions and defective bone remodeling within the 
lumbar spine of Nf1flox/-;Col2.3Cre mice as described above. Consistent with 
these data, we also observed analogous skewing in osteoclast and osteoblast 
frequencies within the distal femur of Nf1flox/-;Col2.3Cre mice [78]. 
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Figure 14. Nf1flox/-;Col2.3Cre mice have increased osteoclast number and 
reduced osteoblast number per mm of bone surface in the upper facet 
processes. (A) (Top panel) Representative photomicrographs (magnification, 
200x) of the upper facet processes of four genotypes of mice following TRACP 
staining. (Bottom panel) Mean osteoclast number per mm of bone surface was 
quantified per 200x field. Data represent mean ± SEM of five fields for each 
genotype. Five mice were used for each group. *P ˂0.01 Nf1+/- vs. WT. **P ˂ 
0.001 Nf1flox/-;Col2.3Cre vs. WT. #P ˂0.05 Nf1flox/-;Col2.3Cre vs. Nf1+/-. ##P ˂ 0.01 
Nf1flox/-;Col2.3Cre vs. Nf1flox/flox;Col2.3Cre. (B) (Top panel) Representative 
photomicrographs (magnification, 200x) of the upper facet processes of four 
genotypes of mice following MacNeal staining. (Bottom panel) Quantitative 
evaluation of the osteoblast number per mm of bone surface. Data represent 
mean ± SEM of five high power fields per mouse and five mice were used in 
each group. *P ˂0.01 Nf1+/- vs. WT. **P < 0.01 Nf1flox/flox;Col2.3Cre vs. WT. ***P 
˂0.001 Nf1flox/-;Col2.3Cre vs. WT. #P ˂ 0.05 Nf1flox/flox;Col2.3Cre vs. Nf1flox/-
;Col2.3Cre. ##P ˂ 0.01 Nf1flox/-;Col2.3Cre vs. Nf1+/-. 
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Dystrophic spinal deformities in Nf1flox/-;Col2.3Cre mice 
 
Enlargement of the spinal canal 
Widening of the spinal canal is one of the characteristic dystrophic 
features of NF1 related spinal deformities [55]. To screen for this phenotype in 
Nf1flox/-;Col2.3Cre mice, the ratio of spinal canal area (C)/vertebral body area (V) 
(C/V ratio) was measured at L5 by pQCT (Figure 15). An increased C/V ratio 
indicates a comparatively larger area of the spinal canal. While vertebral body 
area (V) was unchanged between the four groups of mice (data not shown), 
significant increases in the C/V ratio were observed in Nf1+/-, Nf1flox/flox;Col2.3Cre, 
and Nf1flox/-;Col2.3Cre mice as compared with WT mice, with Nf1flox/-;Col2.3Cre 
mice exhibiting the highest ratio. We postulate that this phenomenon may be 
related to compression mediated by the cerebrospinal fluid, whereby outward 
pressure of the dural sac pushing against the weakened trabecular bone of the 
Nf1flox/-;Col2.3Cre vertebral body leads to enlargement of the spinal canal. 
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Figure 15. Enlargement of the spinal canal in Nf1flox/-;Col2.3Cre mice. The 
ratio of spinal canal area/vertebral body area (C/V) was compared between the 
four groups of mice. Data represent mean ± SEM of 9–10 mice per genotype. *P 
˂ 0.05 Nf1+/- vs. WT. **P ˂ 0.01 Nf1flox/flox;Col2.3Cre vs. WT. ***P ˂ 0.001 Nf1flox/-
;Col2.3Cre vs. WT. #P ˂ 0.05 Nf1flox/-;Col2.3Cre vs. Nf1flox/flox;Col2.3Cre. ##P ˂ 
0.01 Nf1flox/-;Col2.3Cre vs. Nf1+/-. 
92 
Vertebral dysplasia with interarticular fusion 
Dysplastic deformation of the vertebral bodies is one of the hallmark 
features of dystrophic scoliosis in NF1. Here, we demonstrate progressive 
dysplastic deformation of the vertebral bodies occurring within focal segments of 
the Nf1flox/-;Col2.3Cre axial spine, as shown in plain radiographs (Figure 16A) 
and by µCT (Figure 16B). Histological sections acquired from mice one, two, six, 
and 12 months of age further demonstrate the progressive nature of the 
phenotype, whereby dysplastic bone remodeling within the intervertebral disc 
space culminates with interarticular fusion of the dystrophic vertebral segments 
(Figure 16C). While the mechanisms mediating this phenotype are unclear, this 
anomaly was observed exclusively in Nf1flox/-;Col2.3Cre mice, suggesting that 
interactions between Nf1 nullizygous osteoblasts and other Nf1 heterozygous 
lineages within the disc space or elsewhere may play a significant role in the 
penetrance of the phenotype. 
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Figure 16. Vertebral dysplasia with progressive interarticular fusion in 
Nf1flox/-;Col2.3Cre mice. (A) Anterior-posterior (i, iii) and lateral (ii, iv) 
radiographs demonstrate vertebral dysplasia in Nf1flox/-;Col2.3Cre mice with 
interarticular fusion of dystrophic vertebrae. (B) Representative µCT 
reconstructions of dystrophic vertebral segments in coronal (top, i and ii) or 
sagittal (bottom, iii and iv) cross-section. Dysplastic bone growth within the 
intervertebral disc space has led to interarticular fusion of the dystrophic 
vertebrae. (C) Representative photomicrographs characterize progressive boney 
dysplasia within the intervertebral disc space of mice at one month (i and ii), two 
months (iii and iv), six months (v and vi), and 12 months (vii and viii) of age. 
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Reduced bone volume fraction and disrupted trabecular microarchitecture in 
dysplastic vertebral bone from Nf1flox/-;Col2.3Cre mice and in a human NF1 
patient with dystrophic scoliosis 
To further investigate the pathological changes in bone microarchitecture, 
µCT scans were performed on dystrophic vertebrae harvested from Nf1flox/-
;Col2.3Cre mice and compared to corresponding segments from age-matched 
WT animals. Bone microarchitecture parameters including bone volume fraction 
(BV/TV, %), trabecular number (Tb.N, mm-1), and trabecular spacing (Tb.Sp, µm) 
were significantly altered in dystrophic Nf1flox/-;Col2.3Cre vertebrae versus 
controls (Figure 17). As a clinical correlate, we compared the bone mass and 
trabecular microarchitecture parameters (Figure 18, Table 2) in the T5 facet from 
a NF1 patient with dystrophic scoliosis and the T7 facet from a matched control 
with idiopathic scoliosis. These specimens were obtained from our collaborator, 
Dr. David Stevenson, at the University of Utah. Consistent with the murine data, 
BV/TV and trabecular microarchitecture parameters were significantly 
compromised in the NF1 T5 facet as compared to the control. Collectively, these 
findings suggest that underlying deficits in bone quality may be a contributory 
factor in the pathogenesis of dystrophic scoliosis in NF1.  
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Figure 17. Reduced bone mass and altered trabecular microarchitecture in 
dystrophic Nf1flox/-;Col2.3Cre vertebrae. Percent bone volume (BV/TV, %), 
trabecular number (Tb.N), and trabecular spacing (Tb.Sp) were calculated by 
µCT as shown above. n = 5. *P < 0.05, **P < 0.01, ***P < 0.001 as compared to 
WT. 
100 
 
Figure 18 
101 
Figure 18. Representative µCT reconstructions of the T5 facet from an NF1 
patient with dystrophic scoliosis and the T7 facet from an age/sex matched 
scoliosis patient without NF1. 
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Table 2 
Microarchitecture Parameters Control – T7 Facet NF1 – T5 Facet 
BV/TV 0.6680 0.2992 
Conn. D. (mm-3) 146.1781 77.1829 
Tb.N (mm-1) 6.8418 3.0513 
Tb.Th (mm) 0.1999 0.1030 
Tb.Sp (mm) 0.0969 0.2457 
BS/BV (mm-1) 10.4599 19.5740 
DA 1.3841 1.6518 
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Table 2. Quantitative parameters of bone microarchitecture were assessed by 
µCT in the T5 facet of an NF1 patient with scoliosis versus the T7 facet of a 
control patient with scoliosis but without NF1. 
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Tibial fracture non-union (pseudarthrosis) in Nf1flox/-;Col2.3Cre mice 
Approximately 3% of young children with NF1 acquire pseudarthrosis, 
fracture non-union which responds poorly to treatment and often requires 
amputation of the affected limb. Given that at least a subset of patients exhibit 
biallelic inactivation of NF1 in fibrous tissue within the fracture site, while 
maintaining a single functional NF1 allele in other tissues [80, 81], we tested 
whether Nf1flox/-;Col2.3Cre and Nf1flox/-;PeriCre mice with an analogous genetic 
framework might recapitulate the pseudarthrotic phenotype. Tibial fractures were 
induced by the three-point bending method as first described by Bonnarens and 
Einhorn [137]. Radiographic assessment of fracture healing at 14 and 28 days 
post fracture revealed persistent non-union in Nf1flox/-;Col2.3Cre mice as 
compared to controls (Figure 19A). Similarly, while 100% of WT mice 
demonstrated radiographic union of the fracture after four weeks, only 15% of 
Nf1flox/-;PeriCre mice showed cortical bridging after four weeks (Figure 19B). This 
percentage plateaued near 60% after eight weeks of monitoring, such that  
approximately 40% of Nf1flox/-;PeriCre mice exhibited persistent radiographic non-
union eight weeks post-fracture. By contrast, conditional Nf1 nullizygosity in 
MSCs and/or osteoblasts alone in the context of a WT background 
(Nf1flox/flox;PeriCre and Nf1flox/flox;Col2.3Cre mice) was insufficient to cause 
appreciable deficits in fracture healing (Figure 19A, B). We therefore reasoned 
that complex interactions between Nf1-/- MCSs/osteoblasts and at least a subset 
of other Nf1 heterozygous lineages must be required for the pathogenesis of 
fracture non-union in Nf1flox/-;PeriCre and Nf1flox/-;Col2.3Cre mice. 
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To test whether Nf1 haploinsufficiency within the hematopoietic 
microenvironment might play a critical role in the pathogenesis of recalcitrant 
fracture healing in Nf1flox/-;PeriCre and Nf1flox/-;Col2.3Cre mice, we transplanted 
BMMNCs from either WT or Nf1+/- donor mice into lethally irradiated Nf1flox/-
;Col2.3Cre or Nf1flox/flox;Col2.3Cre recipients [78]. After four months of 
hematopoietic reconstitution, the recipient mice underwent three-point bending 
fracture. The fracture healing process was monitored for four weeks. 
Nf1flox/flox;Col2.3Cre mice reconstituted with Nf1+/- bone marrow cells exhibited 
severe deficits in fracture repair as compared to controls transplanted with WT 
hematopoietic cells. µCT revealed defective callus formation and significantly 
reduced fractional bone volume (BV/TV) within the fracture sites of 
Nf1flox/flox;Col2.3Cre mice reconstituted with Nf1+/- bone marrow cells as 
compared to WT (Figure 19C). Conversely, adoptive transfer of WT 
hematopoietic cells to Nf1flox/-;Col2.3Cre recipient mice rescued fracture healing 
deficits in these animals. Histologically, mice reconstituted with Nf1+/- marrow 
showed significantly increased numbers of TRACP positive staining osteoclasts 
within areas of recalcitrant fracture healing (Figure 19D), suggesting that perhaps 
increased osteoclast bone resorptive activity may contribute to persistent non-
union in these mice.  
In sum, these data provide rigorous evidence that at least some 
component of the Nf1 haploinsufficient hematopoietic microenvironment plays a 
pivotal role in the pathogenesis of tibial fracture non-union in the Nf1flox/-
;Col2.3Cre and Nf1flox/-;PeriCre murine NF1 pseudarthrosis models. However, the 
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specific lineage(s) within the hematopoietic system that are critical for the 
pathological bone repair process remain unclear. Studies undertaken to further 
investigate this topic are described in Chapter 4. 
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Figure 19. Nf1+/- hematopoietic cells are necessary for tibial fracture non-
union in Nf1flox/-;Col2.3Cre and Nf1flox/-;PeriCre mice. (A) Representative 
radiographs of the fracture site were acquired at 14 and 28 days post-fracture to 
monitor healing. (B) Percent of healed fractures at serial time points as defined 
radiographically by complete cortical bridging across the fracture site. (C) 
Fracture healing was monitored in Nf1flox/flox and Nf1flox/-;Col2.3Cre mice 
previously transplanted with either WT or Nf1+/- bone marrow. Representative 
µCT reconstructions with quantification of bone volume fraction (BV/TV) within 
the callus site are shown. (D) Representative photomicrographs show MacNeal 
staining (upper panels 200x magnification) and TRACP staining (lower panels, 
200x magnification) of fractured tibiae from Nf1flox/flox and Nf1flox/-;PeriCre mice 
reconstituted with either WT or Nf1+/- bone marrow. 
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Discussion 
Skeletal manifestations including osteoporosis, short stature, 
kyphoscoliosis, and tibia pseudarthrosis cumulatively affect greater than 50% of 
NF1 patients [36]; however, our cellular and molecular understanding of these 
osseous defects remains limited due to the lack of animal models which 
accurately recapitulate these phenotypes. Here we describe the generation and 
phenotypic characterization of two novel NF1 murine models: Nf1flox/-;Col2.3Cre 
and Nf1flox/-;PeriCre mice, which exhibit multiple skeletal deficits including runting 
(short stature), low bone mass, spinal deformities, and tibial fracture non-union 
[77, 78] – features closely reminiscent of the human disease. These models thus 
serve as a valuable platform for further investigation of the cellular and molecular 
underpinnings of NF1 osseous manifestations as described in the subsequent 
chapters of this thesis. 
Loss of Nf1 heterozygosity (LOH) together with Nf1 haploinsufficiency in 
the microenvironment has been found to play a critical role in at least two 
malignant manifestations of NF1, including plexiform neurofibromas and optic 
gliomas [84, 139, 140]. Our present study provides genetic evidence that a 
similar paradigm underlies the pathogenesis of NF1-related skeletal defects, 
particularly tibial pseudarthrosis. Through a series of adoptive bone marrow 
transfer experiments, we have demonstrated that the Nf1 haploinsufficient 
hematopoietic microenvironment is critical to the pathogenesis of tibial fracture 
non-union in Nf1flox/-;Col2.3Cre and Nf1flox/-;PeriCre mice [78]. These data are 
consistent with recent clinical data suggesting that at least a subset of NF1 
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pseudarthrosis patients exhibit biallelic NF1 inactivation within tissue 
microdissected from the fracture site, while retaining a single functional NF1 
allele in the peripheral blood [80, 81]. However, which specific Nf1+/- 
hematopoietic lineage(s) play a pivotal role in this process remains unclear. 
Given that Nf1+/- osteoclasts exhibit multiple gain-in-functions [69-72] and are 
abundantly present in pseudarthrosis tissue from human NF1 patients [62, 64, 
65] and mouse models [76, 78, 79, 138, 141], we postulate that hyperactive bone 
resorbing Nf1+/- osteoclasts may be the culprit hematopoietic mediators of tibial 
fracture non-union in Nf1flox/-;Col2.3Cre mice. Studies undertaken to test this 
hypothesis are described in Chapter 4 of this thesis. 
Beyond generalized bone mass deficits in the femur and lumber spine, we 
further demonstrate that Nf1flox/-;Col2.3Cre mice recapitulate many of the 
characteristic dysplastic boney features of NF1 patients with dystrophic scoliosis 
including widening of the spinal canal and dysplastic deformation of the vertebral 
bodies with progressive destruction of the intervertebral disc space and fusion of 
adjacent vertebral segments. While the mechanisms of dystrophic scoliosis in 
NF1 remain unclear, it is has been debated whether these spinal deformities are 
primary osseous defects or occur secondary to the pressure of an adjacent 
paraspinal tumor [52, 142]. Casselman and colleagues speculated that NF1 bone 
is intrinsically more susceptible to the distorting effects of an adjacent tumor 
[143]. In 1986, Sartoris et al. published the first case report documenting the 
fusion of vertebral segments in an NF1 patient [144]. In this case, the patient 
presented with destruction of the L1-L2 vertebral bodies and intervertebral disk 
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space. A presumptive diagnosis of neuropathic arthropathy was made, whereby 
destruction of the bone and articular cartilage is thought to occur secondary to 
loss of neurosensory feedback from the affected joint. In this patient, a 
retroperitoneal neurofibroma was identified anterior to the L1-L2 interspace; 
however, no neurofibromatosis tissue was found within the disk space itself. 
Thus, questions remain as to whether this lesion was primarily neuropathic or 
osteopathic in nature. 
Intriguingly, a recent genetic study of mice harboring conditional Nf1 
nullizygous osteochondroprogenitor cells driven by the Col2α1-Cre (collagen, 
type II, alpha 1) promoter demonstrated congenital intervertebral disc formation 
defects, with improper segmentation of the notochord and impaired proliferation 
of the nucleus pulposus accompanied by interarticular vertebral fusion across 
multiple levels of the spine [141]. In the present study, we utilized the 2.3kb 
segment of the α(I)-Collagen promoter to achieve a more restricted biallelic 
ablation of Nf1 in the osteoblast lineage. In this model, dystrophic vertebral 
features including fusion were observed only when conditional Nf1 nullizygous 
osteoblasts were superimposed on a Nf1+/- background, suggesting that Nf1 
heterozygosity in surrounding tissues and cell lineages may play a critical role in 
the pathogenesis of such osseous defects. 
µCT revealed reduced fractional bone volume and disrupted trabecular 
microarchitecture within dysplastic Nf1flox/-;Col2.3Cre vertebral segments as well 
as the T5 facet of a human NF1 patient with dystrophic scoliosis as compared to 
the T7 facet of an age/sex matched scoliosis patient without NF1. Dynamic 
115 
histomorphometric analysis demonstrated disrupted bone remodeling in Nf1flox/-
;Col2.3Cre vertebrae as compared to WT controls, suggesting that intrinsic 
deficiencies in osteoblast anabolic activity, coupled with enhanced osteoclast 
catabolic activity, may at least partially underlie the pathogenesis and/or 
progression of NF1 dystrophic spinal deformities.  
The vertebrae in quadrupeds do not receive an axial load to maintain 
balance of the torso, which is the major loading mechanism in bipeds [145]. The 
differing mechanical circumstances between bipeds and quadrupeds may explain 
why Nf1flox/-;Col2.3Cre mice do not recapitulate the sharp, angulated curves seen 
in NF1 patients with dystrophic scoliosis. Consistent with this hypothesis, it has 
been demonstrated that scoliotic deformities can be induced with 100% 
penetrance in rats attaining bipedal posture after undergoing surgical amputation 
of the tail and forelimbs [146]. 
Regardless of this discrepancy, these data support the paradigm that 
dystrophic vertebral manifestations in NF1 may indeed arise de novo from 
primary defects in bone cell function, rather than merely as a secondary 
consequence to the paracrine or mass effects of a paraspinal neurofibroma. 
Moreover, this murine model provides a useful platform for further investigation 
regarding the basic cellular and molecular mechanism(s) underlying the 
pathogenesis of dystrophic spinal deformities in NF1. 
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CHAPTER 4. NF1 HAPLOINSUFFICIENT MYELOID PROGENITORS: 
CRITICAL MEDIATORS OF BONE LOSS AND FRACTURE NON-UNION IN 
THE NF1 MURINE MODEL 
 
Introduction 
Loss of NF1 heterozygosity (LOH) in various tissue types has been 
implicated in multiple neoplastic features of NF1, including juvenile 
myelomonocytic leukemia (JMML) [67, 68, 147] and malignant peripheral nerve 
sheath tumor (MPNST) [148, 149]. Clinical studies indicate that at least some 
NF1 pseudarthrosis patients exhibit NF1 nullizygosity in the bone tissue by 
microdissection, suggesting that localized LOH may be a key initiating event 
promoting the pathogenesis of these lesions [80, 81]. Yet recent data also imply 
that Nf1 haploinsufficiency pivotally impacts cell fate and function, contributing to 
the pathogenesis of a range of non-malignant NF1 phenotypes including 
plexiform neurofibroma development [84, 89], vascular disease [150], and 
osteopenia [69, 72, 74, 78, 138].  
Through a series of adoptive bone marrow transfer experiments, as 
outlined in Chapter 3, we have established that haploinsufficiency of Nf1 in the 
hematopoietic microenvironment plays a key role in tibial fracture non-union [78]. 
Transplantation of Nf1+/- bone marrow cells to lethally irradiated 
Nf1flox/fox;Col2.3Cre mice (harboring conditional Nf1-/- osteoblasts with a WT 
background) induced recalcitrant fracture healing as compared to controls 
reconstituted with WT bone marrow. Conversely, adoptive transfer of WT 
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hematopoietic cells to Nf1flox/-;Col2.3Cre mice (harboring Nf1-/- osteoblasts with a 
Nf1+/- background) was sufficient to prevent tibial fracture non-union in these 
animals. Collectively, these data provide rigorous evidence that at least some 
component of the Nf1 haploinsufficient bone marrow microenvironment plays a 
critical role in NF1 skeletal manifestations such as tibial pseudarthrosis. Yet the 
culprit cell lineage(s) within the Nf1+/- hematopoietic system which underlie the 
pathogenesis of fracture non-union remain unclear. 
Hematopoietic-derived osteoclasts are abundantly present in 
pseudarthrotic tissues of NF1 patients [62, 64, 65] and in mouse models of the 
disease [76, 78, 79, 138, 141]. Mononuclear cells cultured ex vivo from the 
peripheral blood of NF1 patients [69-71] and the bone marrow of Nf1+/- mice [69, 
72] exhibit enhanced osteoclast differentiation and bone resorptive capacity, 
driven by Ras-mediated hypersensitivity to limiting doses of M-CSF and RANKL 
[69]. Yet the stage of myeloid/osteoclast development at which Nf1 
haploinsufficiency is permissive of these gain-in-functions remains unclear. Cell 
autonomous osteoclast gain-in-functions driven intrinsically through Ras- 
dependent signaling pathways are difficult to segregate from confounding 
alterations in extrinsic cytokine levels within the bone microenvironment. It has 
been postulated that hypersecretion of osteopontin (OPN) by Nf1 mutant 
osteoblasts [85] together with alterations in the RANKL/osteoprotegerin (OPG) 
cytokine ratio [75] may contribute significantly to enhancing osteoclast 
recruitment and bone catabolic activity in vivo. The potential contribution of 
paracrine effects mediated by other Nf1 haploinsufficient hematopoietic lineages 
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including B-cells [151], T-cells [152], and megakaryocytes [153, 154] are equally 
difficult to ascertain. 
To address these unanswered questions and achieve deeper insight into 
the cell autonomous role of Nf1 gene dose in regulating myeloid/osteoclast 
development, we generated Nf1flox/+;LysMCre and Nf1flox/+;CtskCre mice 
harboring conditional inactivation of a single Nf1 allele in myeloid osteoclast 
progenitors and mature osteoclasts, respectively. Here we demonstrate that 
haploinsufficient loss of Nf1 in early stage myeloid precursors, not merely in 
terminally differentiated osteoclasts alone, is required to induce accelerated 
osteoclast catabolic activity and bone loss in vivo. BMMNCs cultured from 
Nf1flox/+;LysMCre mice, but not Nf1flox/+;CtskCre mice, exhibit increased 
osteoclast progenitor frequency, M-CSF hypersensitivity in methylcellulose 
colony formation assays, and increased osteoclast differentiative capacity. 
Moreover, we provide direct genetic evidence through adoptive bone marrow 
transfer that cooperative interactions between Nf1 nullizygous osteoblasts and 
Nf1 haploinsufficient osteoclasts within the hematopoietic microenvironment 
pivotally underlie the pathogenesis of tibial fracture non-union in Nf1flox/-
;Col2.3Cre mice. Collectively, these data offer novel insights regarding the 
differential and reciprocal roles of Nf1 in terminally differentiated osteoclasts 
versus early stage hematopoietic/myeloid progenitors while establishing the 
critical role of this lineage in the pathogenesis of NF1 non-union fracture. This 
provides important implications for optimizing novel and currently existing 
targeted therapies. 
119 
 
Conditional Nf1 haploinsufficiency in myeloid lineages increases 
osteoclast progenitor frequency and enhances osteoclast differentiation 
Osteoclastogenesis is a dynamic process requiring the commitment and 
proliferation of early myeloid progenitors, followed by differentiation to monocytes 
and ultimately to multinucleated osteoclasts with bone resorptive activity. 
Mononuclear cells isolated from the bone marrow of Nf1+/- mice [69, 72] and 
peripheral blood of human NF1 patients [69-71] exhibit an increased capacity for 
osteoclast differentiation and bone resorption in vitro, due to Ras-mediated 
hypersensitivity to osteoclastogenic cytokines such as M-CSF and RANK-L [69]. 
Yet no genetic study has directly assessed the stage of myeloid/osteoclast 
development at which Nf1 haploinsufficiency is permissive of osteoclast gain-in-
functions. To assess the cell autonomous role of Nf1 in early versus late stage 
osteoclastogenesis, we began by comparing the commitment and proliferative 
capacity of myeloid/osteoclast progenitor cells in the bone marrow of 
Nf1flox/+;LysMCre, Nf1flox/+;CtskCre, and wild-type (WT) control mice. BMMNCs 
were cultured in semisolid methylcellulose media over a range of concentrations 
of M-CSF. We found that the number of colony forming unit-macrophage (CFU-
M) per femur were significantly increased in Nf1flox/+;LysMCre mice versus WT 
with increasing doses of M-CSF (Figure 20A). In addition, flow cytometric 
analysis of the bone marrow revealed a significant increase in the present of 
myeloid progenitors (Figure 20B). Thus, haploinsufficient loss of Nf1 induced by 
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LysMCre at the early progenitor stage is sufficient to expand the pool of myeloid 
precursors that have the potential to mature into fully differentiated osteoclasts. 
Given the increase in the number of myeloid/osteoclast progenitors in 
Nf1flox/+;LysMCre mice, we next determined the capacity of BMMNCs isolated 
from these mice to differentiate to mature osteoclasts in tissue culture. When 
BMMNCs were cultured in the presence of M-CSF and RANK-L, a significant 
increase in the number of TRACP positive staining multinucleated osteoclasts 
was observed in the Nf1flox/+;LysMCre cultures as compared to WT controls 
(Figure 20C). The number of nuclei per osteoclast was also significantly 
increased in the Nf1flox/+;LysMCre cultures (Figure 20C), a phenotype that is 
characteristic of osteoclasts cultured from the bone marrow of Nf1+/- mice [69, 72] 
and the peripheral blood of human NF1 patients [69-71]. 
A defining morphological feature of mature osteoclasts is the organization 
of the actin cytoskeleton to form a specialized cell–extracellular matrix that 
provides the proper microenvironment for degradation of bone matrix. This 
complex structure is formed by the coalescence of actin cytoskeletal structures 
termed podosomes that arrange into identifiable patterns such as clusters, rings, 
and ultimately belts that constitute a functional sealing zone [155]. Here, we 
show that compared to WT controls, Nf1flox/+;LysMCre osteoclast cultures exhibit 
significantly higher levels of belt formation (Figure 20D), a cellular characteristic 
correlating with bone resorptive activity [72]. 
By contrast, when we assessed the osteoclast forming potential of 
BMMNCs flushed from the long bones of Nf1flox/+;CtskCre mice, we observed no 
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significant differences in the number of TRACP positive staining multinucleated 
osteoclasts as compared to WT controls (Figure 20E). Collectively, these findings 
led us to reason that the enhanced osteoclastogenic potential of Nf1 
haploinsufficient bone marrow cells may in fact require genetic disruption of a 
single Nf1 allele in the early stage myeloid progenitor population, before these 
osteoclast precursors undergo terminal lineage commitment and differentiation. 
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Figure 20. Nf1 haploinsufficiency in myeloid progenitors potentiates 
osteoclast differentiation. (A) The number of colony forming unit-
monocyte/macrophage (CFU-M) per femur were enumerated following seven 
days culture in semisolid methylcellulose media. **P < 0.01, ***P < 0.001 
Nf1flox/+;LysMCre vs. WT. n = 8 mice per genotype. (B) Populations of GMP, 
myeloid cells, and monocytes in the bone marrow were identified by flow 
cytometry. Fold changes in the number of cells per femur are reported. *P < 0.05 
Nf1flox/+;LysMCre vs. WT. n = 4 mice per genotype. (C) Representative 
photomicrographs show TRACP staining of bone marrow derived osteoclasts 
cultured from WT and Nf1flox/+;LysMCre mice in the presence of M-CSF and 
RANKL for six days (top panel). The number of osteoclasts per high power field 
(HPF) and the number of nuclei per osteoclast were counted as shown (bottom 
panel). **P < 0.01, ***P < 0.001 Nf1flox/+;LysMCre vs. WT. n = 4 biological 
replicates per genotype. (D) Representative photomicrographs show actin ring 
formation in bone marrow derived osteoclast cultures at 50x and 200x 
magnification (top panel). Cells were stained with Alexa Fluor® 488 Phalloidin 
(green) and Hoechst (blue). Podosome formation was evaluated by determining 
the percent distribution of actin organization into clusters, rings, and belts (bottom 
panel). *P < 0.05 Nf1flox/+;LysMCre vs. WT. n = 4 biological replicates per 
genotype. (E) Representative photomicrographs show TRACP staining of bone 
marrow derived osteoclasts cultured from WT and Nf1flox/+;CtskCre mice in the 
presence of M-CSF and RANKL for six days (top panel) The number of 
osteoclasts per HPF and the osteoclast area per HPF were quantified as shown 
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(bottom panel). n = 3 biological replicates per genotype. ns = no significant 
difference. 
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Haploinsufficient Nf1 deletion in myeloid progenitor cells potentiates bone 
erosive activity in vivo 
Although Nf1+/- mice exhibit increased osteoclast numbers [69], their bone 
mass does not differ significantly from WT controls [74]. Likewise, we observed 
no significant differences in BMD, bone mass, or trabecular architecture between 
either Nf1flox/+;LysMCre (Figure 21A, B) or Nf1flox/+;CtskCre mice (Figure 22A, B) 
and their WT counterparts. By contrast, we have previously demonstrated that 
Nf1+/- mice lose significantly more bone mass (by a factor of 2) as compared to 
WT controls when challenged with ovariectomy induced proresorptive stress [69]. 
To further characterize the functional consequences of Nf1 haploinsufficiency in 
osteoclasts and their progenitors in response to proresorptive challenge, we 
ovariectomized Nf1flox/+;LysMCre and Nf1flox/+;CtskCre mice and compared the 
extent of bone loss to WT controls.  
As anticipated, the OVX procedure induced bone loss in all genotypes of 
mice (Figure 23A, B). Notably, the rate of bone loss was markedly accelerated in 
Nf1flox/+;LysMCre-OVX mice. The percentage reduction in femoral BMD was 
significantly greater in Nf1flox/+;LysMCre-OVX mice as compared to either 
ovariectomized WT animals or sham-operated controls during the six week 
period (Figure 23A). Representative µCT reconstructions show a dramatic loss of 
trabecular bone in Nf1flox/+;LysMCre-OVX mice as compared to WT-OVX and 
sham controls (Figure 23B). Quantitative µCT evaluation revealed significant 
differences in femoral bone volume fraction (Figure 23C) and multiple bone 
microarchitecture parameters, including trabecular number (Tb.N), trabecular 
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thickness (Tb.Th), and trabecular spacing (Tb.Sp) (Figure 23D). Intriguingly, 
however, Nf1flox/+;CtskCre mice did not recapitulate this phenotype. Although 
bone mass was reduced in both WT- and Nf1flox/+;CtskCre-OVX mice, no 
significant difference in the percentage reduction in femoral BMD between the 
two strains was observed (Figure 23E). Representative µCT reconstructions 
demonstrate equivalent bone loss in the distal femur when comparing WT-OVX 
and Nf1flox/+;CtskCre-OVX mice. Quantitatively, no significant difference was 
detected in femoral bone volume fraction (Figure 23F) or trabecular architecture 
parameters (Figure 23G) between Nf1flox/+;CtskCre-OVX versus WT-OVX mice. 
Collectively, these data suggest that conditional Nf1 haploinsufficiency in 
terminally differentiated osteoclasts is insufficient to trigger increased bone lytic 
activity in response to proresorptive challenge. Rather, genetic ablation of a 
single Nf1 allele in myeloid progenitors may be required to expand the pool of 
osteoclast precursors, thereby promoting accelerated bone resorption in vivo. 
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Figure 21. Haploinsufficient loss of Nf1 in myeloid lineages does not 
spontaneously alter bone mass or trabecular microarchitecture in vivo. (A) 
Representative μCT reconstructed femora of WT and Nf1flox/+;LysMCre mice in 
transverse (top) and longitudinal (bottom) cross-sections. (B) No significant 
differences in bone volume fraction (BV/TV), connectivity density (Conn.D.), 
trabecular number (Tb.N), trabecular spacing (Tb.Sp), and trabecular thickness 
(Tb.Th), bone surface/bone volume ratio (BS/BV), or structure model index (SMI) 
were found when comparing WT to Nf1flox/+;LysMCre mice. n = 5-8 per group. 
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Figure 22. Nf1flox/+;CtskCre mice have equivalent bone mass and trabecular 
architecture parameters to WT controls. (A) Representative μCT 
reconstructed femora of WT and Nf1flox/+;CtskCre mice in transverse (top) and 
longitudinal (bottom) cross-sections. (B) No significant differences in bone 
volume fraction (BV/TV), connectivity density (Conn.D.), trabecular number 
(Tb.N), trabecular spacing (Tb.Sp), trabecular thickness (Tb.Th), bone 
surface/bone volume ratio (BS/BV), structure model index (SMI), or density 
anisotropy (DA) were found when comparing WT versus Nf1flox/+;CtskCre mice. n 
= 6-7 per group. 
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Figure 23. Nf1 haploinsufficiency in myeloid progenitors potentiates bone 
loss in response to OVX mediated proresorptive challenge. (A) The percent 
change in femoral BMD for WT and Nf1flox/+;LysMCre mice was determined by 
pDEXA measurements acquired before and six weeks after either sham or OVX 
surgery. n = 5 sham, 8-10 OVX mice per genotype.*P < 0.05. (B) Representative 
μCT reconstructed femora in longitudinal (top) and transverse (bottom) cross-
sections for WT versus Nf1flox/+;LysMCre mice six weeks following either sham or 
OVX surgery. (C) Trabecular bone volume fraction (BV/TV) was quantified in the 
distal femur by μCT. n = 6 sham, 7-12 OVX mice per genotype. *P ˂ 0.05. (D) 
Parameters of trabecular microarchitecture including trabecular number (Tb.N), 
trabecular spacing (Tb.Sp), and trabecular thickness (Tb.Th) were quantified as 
shown. n = 6 sham, 7-12 OVX mice per genotype. *P ˂ 0.05, **P ˂ 0.01. (E) 
Representative μCT reconstructed femora in longitudinal (top) and transverse 
(bottom) cross-sections for WT versus Nf1flox/+;CtskCre mice six weeks following 
either sham or OVX surgery. (F) No significant difference was observed in the 
percent change in femoral BMD between WT and Nf1flox/+;CtskCre six weeks-
post OVX surgery. n = 6-7 sham, 10-15 OVX mice per genotype. (G) Femoral 
BV/TV was quantified by μCT as shown and revealed no significant difference 
between WT and Nf1flox/+;CtskCre mice. n = 5 sham, 12 OVX mice per genotype. 
(H) No significant differences in trabecular microarchitecture parameters were 
found when comparing connectivity density (Conn.D.), trabecular number (Tb.N), 
trabecular spacing (Tb.Sp), and trabecular thickness (Tb.Th), bone surface/bone 
volume ratio (BS/BV), or structure model index (SMI) between WT and 
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Nf1flox/+;CtskCre mice undergoing OVX surgery. n = 5 sham, 12 OVX mice per 
genotype. 
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Cooperative interactions between Nf1 haploinsufficient myeloid cells and 
Nf1 nullizygous osteoblasts are required to induce tibial fracture non-union 
in Nf1flox/-;Col2.3Cre mice 
It has been hypothesized that NF1 osseous defects, in particular 
pseudarthrosis, may require the heterotypic interaction of multiple cell types with 
varying Nf1 gene dosage [86]. Supporting this paradigm, recent clinical data 
confirms that at least a subset of NF1 pseudarthrosis patients exhibit biallelic 
inactivation of NF1 in tissue microdissected from the lesion site [80, 81]. 
Recently, we established that Nf1flox/-;Col2.3Cre mice (harboring conditional Nf1-/- 
osteoblasts and a Nf1+/- background) recapitulate characteristic skeletal 
manifestations found in NF1 patients including tibial fracture non-union [78]. By 
adoptive transfer of WT and Nf1+/- bone marrow cells into Nf1flox/flox;Col2.3Cre 
recipient mice (harboring conditional Nf1-/- osteoblasts), we demonstrated that 
the cooperative interaction between conditional Nf1-/- osteoblasts and Nf1+/- 
hematopoietic cells leads to recalcitrant fracture repair [78]. These data suggest 
that Nf1 haploinsufficiency in at least a subset of hematopoietic lineages is 
integral to the pathogenesis of fracture non-union in this model. Given that Nf1+/- 
osteoclasts exhibit multiple gain-in-functions [69, 72], we therefore hypothesized 
that Nf1 haploinsufficient osteoclasts and their progenitors are the critical 
hematopoietic lineage underpinning fracture non-union in the NF1 murine model. 
To test this hypothesis, we lethally irradiated Nf1flox/flox;Col2.3Cre recipient 
mice and transplanted them with WT and Nf1flox/+;LysMCre donor bone marrow 
cells. After waiting four months to achieve stable hematopoietic reconstitution, a 
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tibial fracture was induced and fracture healing was monitored for three months. 
Nf1flox/flox;Col2.3Cre recipients transplanted with WT bone marrow cells healed 
normally (Figure 24A, B). In contrast, Nf1flox/flox;Col2.3Cre recipients reconstituted 
with Nf1flox/+;LysMCre bone marrow demonstrated persistent tibial fracture non-
union (Figure 24A). Representative µCT reconstructions reveal defective cortical 
bridging across the fracture site (Figure 24B, top panel). Quantitatively, we found 
that the callus bone volume fraction (BV/TV) was significantly reduced in 
recipients reconstituted with Nf1flox/+;LysMCre bone marrow cells as compared to 
WT (Figure 24B, bottom panel). Histologically, we observed infiltration of fibrous 
tissue into the lesion site of Nf1flox/flox;Col2.3Cre mice transplanted with 
Nf1flox/+;LysMCre bone marrow, and an abundance of TRACP positive staining 
osteoclasts (Figure 24C), features which closely recapitulate the human disease 
[62, 64, 65]. 
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Figure 24. Transplantation of Nf1flox/+;LysMCre hematopoietic cells induces 
tibial fracture non-union in mice harboring Nf1 nullizygous osteoblasts. (A) 
Representative radiographs demonstrate tibial fracture healing in 
Nf1flox/flox;Col2.3Cre recipient mice reconstituted with either WT or 
Nf1flox/+;LysMCre donor bone marrow cells. X-rays were acquired one and three 
months post-fracture. (B) Representative μCT reconstructed whole callus (top) 
and longitudinal cross-sections (bottom) from Nf1flox/flox;Col2.3Cre mice 
undergoing bone marrow transplantation and tibial fracture. Callus bone volume 
fraction (BV/TV) was quantified by μCT as shown in the bar graph below. n = 6-8 
mice per group. *P ˂ 0.05. (C) Representative tibial fractures in longitudinal 
cross-section stained with trichrome (25x and 200x magnification), H&E (200x 
magnification), and TRACP (200x magnification). 
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Discussion 
Multiple osteoclast gain-in-functions reported in both Nf1+/- mice and 
human NF1 heterozygous cells are consistent with clinical observations that NF1 
patients have reduced bone mineral density [22-26, 30] and are predisposed to 
increased fracture risk [27, 156]. Yet the precise role of Nf1 in modulating the 
step-wise progression of osteoclast development remains unclear. By 
conditionally inactivating a single Nf1 allele in early versus late stage 
osteoclastogenesis, we demonstrate that conditional Nf1 haploinsufficiency in the 
early stage of myeloid development potentiates osteoclast differentiation and 
bone resorption. Nf1flox/+;LysMCre mice exhibit increased frequency of osteoclast 
progenitors, enhanced osteoclastogenesis, and accelerated bone resorption 
following ovariectomy induced resorptive stress in vivo. Interestingly, 
recombination of the floxed Nf1 allele in terminally differentiated osteoclasts, 
mediated by CtskCre, did not recapitulate these phenotypes in analogous 
experiments. These genetic data implicate haploinsufficient loss of Nf1 in early 
stage myeloid progenitors as a pivotal requirement for potentiating osteoclast 
catabolic activity and bone loss in vivo. Given that genetic ablation of a single Nf1 
allele in terminally differentiated osteoclasts alone is insufficient to augment the 
rate of bone lytic activity, we therefore postulate that proresorptive phenotypes in 
the context of Nf1 haploinsufficiency may be primarily mediated through an 
expansion in the pool of osteoclast precursors and an overall increase in 
osteoclast numbers, as opposed to the enhanced resorptive activity of individual 
osteoclasts themselves.  
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Alanne and colleagues recently reported that transgenic mice harboring 
conditional Nf1 nullizygous (Nf1-/-) osteoclasts driven by TRAP-Cre, exhibit 
increased bone resorptive capacity and aberrant actin ring formation in vitro 
[157]. Despite differences in Nf1 gene dose (heterozygous versus biallelic Nf1 
inactivation), we postulate that the apparent osteoclast gain-in-functions in this 
mouse model are likely due to the expression of TRAP-Cre in more primitive 
stages of osteoclast/myeloid development as compared to Ctsk-Cre, which is 
restricted to mature, terminally differentiated osteoclasts [129]. Supporting this 
concept, the authors report that Nf1flox/flox;TRAP-Cre mice exhibit a number of 
extra-osseous features including splenomegaly and megakaryocytosis [157]. 
These findings are reminiscent of the juvenile myelomonocytic leukemia (JMML)-
like myeloproliferative disease (MPD) phenotypes seen following Nf1 loss of 
heterozygosity (LOH) in the hematopoietic compartment [67, 158-160], and are 
suggestive of TRAP-Cre mediated Nf1 recombination in relatively primitive 
myeloid osteoclast precursors as previously characterized [129]. Given the fact 
that NF1 patients with osteopenia and osteoporosis typically retain a single 
functional NF1 allele, we chose to focus our present studies on the physiological 
consequences of Nf1 heterozygosity in osteoclast development. 
Focal NF1 skeletal abnormalities such as tibial pseudarthrosis occur at a 
lower rate than generalized bone mass deficits, implying that modifying factors – 
such as localized NF1 LOH – may be required to precipitate the pathology. 
Recent clinical data support this concept, demonstrating that at least a subset of 
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NF1 pseudarthrosis patients exhibit NF1 LOH in tissue microdissected from the 
lesion site [80, 81]. Modeling the heterotypic interaction of multiple cell types with 
varying Nf1 gene dosage, we have recently shown that Nf1flox/-;Col2.3Cre mice 
(harboring Nf1-/- osteoblasts on a Nf1+/- background) recapitulate multiple 
osseous deficits seen in the human disease, including low bone mass and tibial 
fracture non-union [77, 78]. Through a series of adoptive bone marrow transfer 
experiments, we have previously shown that cooperative interactions between 
conditional Nf1-/- osteoblasts and Nf1+/- hematopoietic cells are integral to the 
pathogenesis of tibial fracture non-union in Nf1flox/-;Col2.3Cre mice [78]. Still, we 
had yet to identify the culprit lineage(s) within the hematopoietic system which 
were critical for inducing the pathological bone repair process. 
Although osteoclasts are abundantly present in pseudarthrosis tissue 
dissected from human NF1 patients [62, 64, 65] as well as in multiple murine 
models of the disease [76, 78, 79, 138, 141], to date, no study has directly 
assessed the functional significance of Nf1 haploinsufficient osteoclasts and their 
progenitors in the pathogenesis of NF1 fracture non-union. Here, we 
demonstrate that transplantation of Nf1flox/+;LysMCre hematopoietic cells can 
induce tibial fracture non-union in Nf1flox/flox;Col2.3Cre recipient mice. These data 
provide direct genetic evidence that inactivation of a single Nf1 allele in 
osteoclasts and myeloid progenitors pivotally modulates recalcitrant fracture 
healing in a murine NF1 pseudarthrosis model. 
A recent pseudarthrosis model developed by El-Hoss and colleagues 
utilizes the injection of a Cre-expressing adenovirus (AdCre) into the tibia to 
156 
inactivate floxed Nf1 alleles within the fracture site [161]. When comparing 
fractures in Nf1flox/flox and Nf1flox/- mice following injection of AdCre, there were no 
significant differences in the rate of fracture healing between the two strains, 
leading the authors to conclude that the primary deficiency in pseudarthrosis is 
likely to involve “poor Nf1null bone anabolism rather than increased 
responsiveness of Nf1+/- osteoclast precursors [161].” An inherent difficulty 
associated with this approach, however, is the lack of selectivity associated with 
AdCre injection, whereby Cre-mediated recombination of the floxed Nf1 allele(s) 
will occur non-specifically in any cell types present within the lesion, including 
both osteoclast and osteoblast progenitors. In effect, AdCre injection renders 
Nf1flox/flox and Nf1flox/- strains genetically equivalent within the fracture site, 
whereby all cells expressing AdCre effectively become Nf1 nullizygous. This 
could explain why equivocal results were obtained when comparing the Nf1flox/flox 
and Nf1flox/- strains following AdCre injection. By contrast, the results of the 
present study implicate increased bone lytic activity of Nf1+/- osteoclasts as a 
pivotal factor underlying the pathogenesis of tibial fracture non-union in Nf1flox/-
;Col2.3Cre mice. We further contend that a hematopoietic stem cell 
transplantation approach, as utilized herein, provides a rigorous methodology to 
segregate and independently assess the functional roles of Nf1 nullizygous 
osteoblasts versus Nf1+/- osteoclasts and myeloid progenitors in the 
pathogenesis of tibial fracture non-union. 
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CHAPTER 5. HYPERACTIVE TGF-β1 SIGNALING PIVOTALLY UNDERPINS 
OSSEOUS DEFICITS IN NF1 MICE 
 
Introduction 
The molecular mechanisms responsible for low bone mass and 
recalcitrant fracture healing in NF1 patients are not clearly defined, yet 
deregulation of osteoclast and osteoblast function, the principal cellular drivers of 
bone resorption and bone formation, has been widely reported both in NF1 
mouse models [69, 73-75] as well as in osteoblasts and osteoclasts cultured ex 
vivo from human patients with the disease [69-71]. Transforming growth factor-
beta1 (TGF-β1) has become increasingly recognized as a critical mediator of 
physiological and pathological skeletal remodeling. Recently, Tang and 
colleagues demonstrated the pivotal role of TGF-β1 as a master switch 
regulating the spatiotemporal coupling of bone resorption and formation [94]. 
Having previously established that Nf1 haploinsufficient myeloid cells potentiate 
neurofibroma phenotypes through secreted TGF-β signaling [89], we 
hypothesized that analogous paracrine signaling between Nf1 deficient 
osteoblasts and osteoclasts may be integral to the pathogenesis of NF1 skeletal 
defects. 
To determine the functional significance of TGF-β signaling in deregulated 
NF1 bone remodeling, we utilized the Nf1flox/-;Col2.3Cre mouse model, which 
recapitulates characteristic skeletal manifestations found in NF1 patients, 
including low bone mass and tibial non-union fracture [77, 78]. Here, we show 
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that serum TGF-β1 levels are five- to six- fold increased both in Nf1flox/-;Col2.3Cre 
mice and in a cohort of NF1 patients. We further delineate a mechanism by 
which TGF-β1 is hypersecreted from Nf1 deficient osteoprogenitors and acts to 
preferentially enhance Nf1+/- osteoclast bone resorptive activity, while inhibiting 
osteoblast differentiation by Nf1-/- MSCs. By re-expressing the human, full-length 
neurofibromin GTPase-activating protein (GAP)-related domain (NF1 GRD) in 
Nf1 deficient osteoprogenitor cells, we demonstrate that p21-Ras-dependent 
hyperactivation of the canonical TGF-β1-Smad pathway is associated with 
hyperresponsiveness to TGF-β1 signals by Nf1 deficient bone cells. Notably, 
treatment with a pharmacologic inhibitor of TβRI kinase activity (SD-208) rescued 
bone mass defects and prevented tibial fracture non-union in Nf1flox/-;Col2.3Cre 
mice. Collectively, these data implicate dysregulated TGF-β1 signaling as a 
primary factor underlying the pathogenesis of NF1 associated osteoporosis and 
pseudarthrosis. Moreover, modulation of TGF-β signaling may serve as a 
potential therapeutic target in the treatment for NF1 osseous defects which are 
refractory to current modalities. 
 
Nf1 regulates TGF-β1 expression 
In human disease, alterations in TGF-β signaling occur via several 
mechanisms, including aberrant ligand expression/activation, receptor mutations, 
and dysregulation of downstream effectors pathways. We examined the serum 
TGF-β1 levels in Nf1flox/-;Col2.3Cre mice, which closely recapitulate a spectrum 
of osseous manifestations seen in NF1 patients. Strikingly, we found that the 
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serum level of total TGF-β1 in Nf1flox/-;Col2.3Cre mice was five- to six-fold 
elevated as compared to WT controls (Figure 25A). To identify the cell type 
responsible for TGF-β1 overproduction, we examined TGF-β1 expression at the 
mRNA and protein levels from WT, Nf1+/-, and Nf1-/- osteoblast progenitors 
(MSCs), as this lineage is the principal source of TGF-β1 in bone [87]. Nf1+/- and 
Nf1-/- MSCs, as compared with WT cells, expressed significantly more TGF-β1 
mRNA (Figure 25B, top panel) and protein (Figure 25B, bottom panel). Further 
corroborating neurofibromin’s function as a negative regulator of TGF-β1 
expression, we observed significantly increased serum TGF-β1 levels in human 
NF1 patients as compared to healthy controls (Figure 25C). Collectively, these 
data imply that deletion of Nf1 leads to pathological TGF-β1 overproduction in a 
gene dosage-dependent fashion. 
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Figure 25. Nf1 gene dose regulates TGF-β1 production by osteoblasts. (A) 
Serum TGF-β1 levels were measured by ELISA in WT and Nf1flox/-;Col2.3Cre 
mice. n = 4. ****P ˂ 0.0001. (B) TGF-β1 mRNA expression in WT, Nf1+/-, Nf1-/- 
osteoblast progenitors was examined by real-time quantitative RT-PCR. n = 3. 
**P ˂ 0.01, ****P ˂ 0.0001 (top panel). Protein extracts were examined by ELISA 
to determine TGF-β1 protein expression. n = 3. **P ˂ 0.01, ****P ˂  0.0001 
(bottom panel). (C) Serum TGF-β1 levels were measured by ELISA in human 
NF1 patients and healthy controls. n = 7. **P ˂ 0.01. 
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Aberrant Smad signaling mediates dysregulated Nf1 bone cell function 
 
Loss of Nf1 leads to p21-Ras-dependent TGF-β1 overexpression and activation 
of the Smad pathway in MSCs, inhibiting osteoblast differentiation. 
Canonical TGF-β signaling involves the phosphorylation of Smad proteins 
by TβRI [96]. To examine the role of Nf1 in regulating this pathway, we compared 
TGF-β1 induced activation of Smad2 in WT, Nf1+/-, and Nf1-/- MSCs. We 
observed an increase in TGF-β1 induced Smad2 phosphorylation in Nf1-/- 
osteoprogenitors versus WT controls (Figure 26A), while the total protein 
expression of Smad2 (Figure 26A), TGF-β receptor 1 (TβRI), and TGF-β receptor 
2 (TβRII) (Figure 26B) remained constant. To further assess the implications of 
increased TGF-β1 biochemical activity on osteoblastogenesis, WT and Nf1-/- 
MSCs were cultured in osteogenic differentiation medium supplemented with 
TGF-β1. Expression of the osteoblast marker alkaline phosphatase (ALP), which 
is impaired at the basal level in Nf1-/- osteoblasts, was further reduced by 87% in 
Nf1-/- cells as compared to just 53% in WT osteoblast cultures stimulated with 
TGF-β1 (Figure 26C). Application of SD-208, an inhibitor of TβRI activity, was 
effective in attenuating Smad phosphorylation to basal levels (Figure 26D) and in 
rescuing ALP expression (Figure 26E). Collectively, these results corroborate 
neurofibromin’s role as a suppressor of canonical TGF-β1 signaling in 
osteoblasts, whereby haploinsufficient or nullizygous Nf1 gene ablation amplifies 
TGF-β1 signaling through the Smad pathway, exacerbating intrinsic deficits in 
terminal osteoblast differentiation – a critical component of bone anabolism. 
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To further determine if TGF-β1 overproduction and increased canonical 
TGF-β1 signaling via the Smad pathway are direct consequences of p21-Ras 
hyperactivity, Nf1 deficient MSCs were transduced with a recombinant retrovirus 
encoding the full length NF1 GAP-related domain (GRD) and a selectable 
marker, pac, which confers resistance to puromycin [73]. As compared to Nf1-/- 
MSCs expressing MSCV-pac alone, reconstitution of the full length NF1 GRD in 
Nf1 deficient MSCs attenuated the expression of TGF-β1 mRNA transcripts by 
nearly 50% (Figure 26F) and suppressed Smad phosphorylation (Figure 26G) 
following TGF-β1 stimulation. This reduction in TGF-β1 expression and signaling 
in Nf1 deficient MSCs is consistent with the normalization of Ras GTP activity 
following reconstitution with functional NF1 GRD as we have reported previously 
[73]. Collectively, these data implicate increased p21-Ras activity as a direct 
mediator of aberrant TGF-β1 expression and signaling in Nf1 deficient MSCs. 
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Figure 26. Nf1 deficient MSCs exhibit hyperactivation of the Smad pathway 
and impaired osteoblast differentiation in response to TGF-β1. (A) p-Smad2, 
Smad2, and GAPDH levels were detected by western blot in osteoblast 
progenitors stimulated with TGF-β1. The quantitative fold change in p-Smad2 
was determined relative to the loading control as shown in the bar graph above. 
(B) Expression levels of TβRI, TβRII, and β-actin were detected by western blot 
in cell lysates collected from WT,  Nf1+/-, and Nf1-/- osteoblast progenitors. (C) 
Osteoblast progenitors were cultured in osteogenic differentiation medium 
supplemented with TGF-β1. Representative photomicrographs (top panel) show 
alkaline phosphatase (ALP) positive osteoblasts (magnification, 200x). ALP 
expression was quantified and normalized to the WT control as shown (bottom 
panel). n = 3. **P ˂ 0.01, ***P ˂ 0.001. (D) Western blot showing p-Smad2 and β-
actin expression in osteoprogenitors following treatment with TGF-β1 and SD-
208. The bar graph above represents the fold change in p-Smad2 compared to 
the protein loading control. (E) WT and Nf1-/- osteoblast progenitors were cultured 
in osteogenic differentiation medium supplemented with TGF-β1 in the presence 
or absence of SD-208. Representative photomicrographs (top panel) show ALP 
positive osteoblasts (magnification, 100x). The bar graph (bottom panel) shows 
the fold change in ALP activity relative to the WT control. n = 4. **P ˂ 0.01, ***P ˂ 
0.0001. (F) TGF-β1 mRNA expression was measured in Nf1-/- MSCs following 
retroviral transduction with control vector (MSCV-pac) versus the functional, full-
length NF1 GRD construct. n = 3. *P < 0.05. (G) p-Smad2, Smad2, and GAPDH 
levels were detected by western blot in MSCs stimulated with TGF-β1 following 
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transduction with either MSCV-pac or MSCV-NF1 GRD retroviral vectors. The 
quantitative fold change in p-Smad2 was determined relative to the level of total 
Smad2 protein as shown in the bar graph above. 
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Hyperactive TGF-β1-Smad signaling potentiates Nf1+/- osteoclast catabolic 
activity 
Given that TGF-β1 has a pivotal impact on cellular functions of both 
osteoblasts and osteoclasts in bone development, we next examined the effects 
of TGF-β1 on aberrant bone catabolic activity by Nf1 haploinsufficient 
osteoclasts. BMMNCs cultured from Nf1+/- mice demonstrated a significantly 
increased capacity to form TRACP positive staining, multinucleated osteoclasts 
following treatment with TGF-β1 as compared to WT controls (Figure 27A). 
Application of TβRI kinase inhibitor (SD-208) attenuated osteoclast formation in a 
dose dependent fashion, with an observable effect beginning at 100 nM in the 
Nf1+/- cultures as compared to 500 nM in the WT cells (Figure 27B). Actin ring 
formation, a prerequisite for osteoclast bone resorption, was also increased in 
Nf1+/- osteoclasts cultured in the presence of TGF-β1, and suppressed by 
escalating concentrations of SD-208 (Figure 27C). To directly assess the effects 
of TGF-β1 on osteoclast function, WT and Nf1+/- osteoclasts were cultured on 
dentine slices in the presence of TGF-β1. Nf1+/- osteoclasts generated markedly 
increased numbers of resorptive “pits” following treatment with TGF-β1 as 
compared to WT controls (Figure 27D), suggesting that TGF-β1 can 
preferentially activate osteoclast bone resorptive activity in the context of Nf1 
haploinsufficiency. TβRI kinase inhibition attenuated “pit” formation to basal 
levels in both WT and Nf1+/- osteoclast cultures. We further show that Nf1+/- 
osteoclast hyperresponsiveness to TGF-β1 is correlated with increased 
biochemical activity of the canonical TGF-β1/Smad pathway. Increased levels of 
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phosphorylated Smad2 were detected in Nf1+/- osteoclasts stimulated with TGF-
β1, while total levels of Smad2 protein were equivalent between the two 
genotypes (Figure 27E). Osteoclasts cultured from the peripheral blood of a 
human NF1 patient and an age/sex matched healthy control exhibited a similar 
phenotype when treated with TGF-β1 (Figure 27F). Collectively, these data 
indicate that neurofibromin functions to negatively regulate Smad-dependent 
TGF-β1 signaling in osteoclasts, whereby Nf1 haploinsufficiency promotes 
excess osteoclast bone lytic activity via hypersensitivity to TGF-β1 stimulation.
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Figure 27. TGF-β1 potentiates Nf1 haploinsufficient osteoclast gain-in-
functions, which are associated with increased activation of the Smad 
pathway. (A) Osteoclast formation from bone marrow mononuclear cells was 
induced by M-CSF and RANKL, in the presence or absence of TGF-β1. 
Representative photomicrographs show multinucleated osteoclasts 
(magnification, 200x) following TRACP staining. Bar graphs represent the mean 
number of nuclei per osteoclast and the area of TRACP positive multinucleated 
osteoclasts per high power field (HPF), quantified using Image J software. n = 4. 
*P ˂ 0.05, ***P ˂ 0.001. (B) Osteoclast formation was assessed following TGF-β1 
stimulation and increasing doses of SD-208. n = 3. *P ˂ 0.05, **P ˂ 0.01 
comparing Nf1+/- versus WT. (C) Osteoclast formation from BMMNCs was 
induced by M-CSF, RANKL, and TGF-β1 with increasing doses of SD-208. 
Representative photomicrographs showing osteoclast actin rings (magnification, 
200x) after staining with phalloidin (green) and Hoechst (blue). (D) Osteoclast 
bone resorption on dentine slices. Representative photomicrographs show 
resorptive “pits” (magnification, 100x). “Pit” area was quantified as shown by the 
bar graph above. n = 3. ****P ˂ 0.0001. (E) Phosphorylated Smad2 (p-Smad2), 
total Smad2, and β-actin were measured by western blot in pre-osteoclasts 
stimulated with TGF-β1 (1 ng/mL) in the presence or absence of SD-208 (100 
nM). The bar graph shows the fold change in p-Smad2 relative to the loading 
control. (F) Osteoclasts were cultured from the peripheral blood of a NF1 patient 
and a matched, healthy control following TGF-β1 stimulation with or without SD-
208 inhibitor treatment. **P ˂ 0.01, ***P ˂ 0.001. 
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Given that osteoclast gain-in-functions lead to increased bone loss in 
Nf1+/- mice following ovariectomy (OVX)-induced resorptive stress [69], we next 
sought to determine the functional contribution of hyperactive TGF-β1 signaling 
towards increased osteolytic activity in vivo, in the context of Nf1 
haploinsufficiency. WT and Nf1+/- mice underwent OVX or sham surgery followed 
by six weeks treatment with SD-208 (60 mg/kg/day) versus vehicle control. 
Pharmacologic TβRI kinase inhibition efficiently maintained femoral BMD in OVX 
mice as compared to vehicle treatment, where bone loss was approximately two-
fold greater in the Nf1+/- cohort as compared to WT controls (Figure 28A). Three-
dimensional µCT further demonstrated preservation of trabecular bone mass in 
OVX mice treated with SD-208 (Figure 28B, top panel). Trabecular bone volume 
fraction (BV/TV) (Figure 28B, bottom panel) and trabecular microarchitecture 
parameters (Figure 28C) including trabecular number (Tb.N), thickness (Tb.Th), 
spacing (Tb.Sp), and structure model index (SMI) were restored to the level of 
sham-operated controls following SD-208 administration in OVX mice.  
Histological methods corroborated these results (Figure 28D) and 
provided insights regarding the cellular mechanism of the observed phenotype. 
Osteoclast numbers, which were markedly increased in vehicle treated Nf1+/- 
OVX mice, returned to baseline levels following SD-208 treatment (Figure 28E, 
top panel). Serum levels of the C-terminal cross-linking telopeptide of type I 
collagen (CTX), an established biomarker of osteolytic activity, were significantly 
increased in vehicle treated Nf1+/- OVX mice, but normalized after SD-208 
treatment (Figure 28E, bottom panel). Overall, the accentuated response of Nf1+/- 
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OVX mice to TβRI kinase inhibition validates the pivotal role of TGF-β in 
potentiating osteoclast bone erosive activity in the context of Nf1 
haploinsufficiency. 
Pharmacologic TGF-β antagonism is known to exert both anabolic and 
anti-catabolic effects on bone [113, 114]. Although osteoblast numbers were 
equivalent between WT and Nf1+/- mice, TβRI kinase inhibition significantly 
increased the number of osteoblasts on the bone surface in both genotypes of 
mice (Figure 28F). Dynamic histomorphometry performed on Nf1+/- mice 
confirmed that SD-208 treatment significantly increased the bone formation rate 
(BFR) and mineral apposition rate (MAR) (Figure 28G), although no significant 
difference was observed in the mineralizing surface (MS/BS) (Figure 28H). 
Collectively, these data suggest that, in addition to osteoclast inhibition, an 
overall increase in osteoblast number and activity is likely to play a key role in the 
bone sparring effects of TβRI kinase blockade following OVX-induced resorptive 
stress. 
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Figure 28. TGF-β signaling potentiates bone loss in Nf1+/- mice following 
OVX resorptive stress. (A) The percent change in BMD was determined by 
pDEXA measurements before and six weeks after surgery plus treatment. n = 
10-12. *P ˂ 0.05, ***P ˂ 0.001. (B) Representative μCT (top panel) shows 
femoral trabecular bone in sham-operated and OVX mice following six weeks 
treatment with vehicle (1% methylcellulose) or TβRI inhibitor, SD-208 (60 mg/kg), 
administered by daily gavage. Trabecular bone volume fraction (BV/TV) was 
quantified in the distal femur by μCT. n = 10-12. *P ˂ 0.05, ***P ˂ 0.001 (bottom 
panel). (C) Trabecular microarchitecture parameters including connectivity 
density (Conn.D.), trabecular number (Tb.N), trabecular spacing (Tb.Sp), and 
structure model index (SMI) were quantified by μCT in OVX mice receiving SD-
208 treatment as compared to controls. n = 10-12. *P ˂ 0.05, **P ˂ 0.01, ***P ˂ 
0.001. (D) Representative longitudinal sections of hematoxylin and eosin (H&E) 
stained femora (25x magnification) are shown. (E) Osteoclast numbers on the 
bone surface (Oc.N/BS) were counted manually on TRACP stained sections at 
200x magnification. n = 10-12. *P ˂ 0.05, ***P ˂ 0.001 (top panel). Serum levels 
of the C-terminal cross-linking telopeptide of type I collagen (CTX) were 
measured by ELISA. n = 10-12. *P ˂ 0.05, **P ˂ 0.01 (bottom panel). (F) 
Osteoblast numbers on the bone surface (Ob.N/BS) were counted manually on 
H&E stained sections at 200x magnification. n = 10-12. ***P ˂ 0.001. (G) 
Representative fluorescent micrographs demonstrate dual calcein labeling of the 
bone surface in Nf1+/- mice, 100x magnification. The bone formation rate (BFR) 
and mineral apposition rate (MAR) were quantified as shown. n = 3. *P ˂ 0.05, 
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**P ˂ 0.01. (H) The Mineralizing surface (MS/BS) was quantified on dual calcein 
labeled sections. n = 3. ANOVA revealed no significant differences. 
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TβRI inhibition rescues bone defects in Nf1flox/-;Col2.3Cre mice 
Based on these findings, we reasoned that a cycle of uncoupled bone 
remodeling perpetuated by TGF-β1 overproduction and Smad-mediated 
hypersensitivity may pivotally underlie the pathogenesis of bone defects 
observed in the Nf1flox/-;Col2.3Cre murine model. We therefore tested whether 
pharmacologic inhibition of TβRI kinase activity could rescue characteristic NF1 
associated bone defects such as osteoporosis and tibial fracture non-union 
observed in Nf1flox/-;Col2.3Cre mice [77, 78]. Cohorts of three- to four-month-old 
Nf1flox/-;Col2.3Cre mice received treatment with either SD-208 (60 mg/kg/day) or 
the vehicle control (1% methylcellulose in sterile water) daily for four weeks. 
Bone mineral density (BMD) measurements were acquired both pre- and post-
treatment to determine the percent change in BMD during the treatment period 
(Figure 29A). µCT (Figure 29B) and histological sections (Figure 29D and E) of 
the excised bones illustrate the low bone mass phenotype of vehicle treated 
Nf1flox/-;Col2.3Cre mice as compared to WT controls. In contrast, dramatic 
increases in bone mineral density (Figure 29A) and trabecular bone volume 
fraction (Figure 29C) were observed in Nf1flox/-;Col2.3Cre mice treated with SD-
208. Although WT mice began treatment with nearly twice the bone mass of 
Nf1flox/-;Col2.3Cre mice prior to therapy, we observed no significant differences in 
bone mass or trabecular architecture parameters (Figure 29C) between WT and 
Nf1flox/-;Col2.3Cre mice following SD-208 treatment, indicating that 
pharmacologic TGF-β inhibition completely rescued bone mass defects in the 
Nf1flox/-;Col2.3Cre mice. On the cellular level, osteoblast numbers, which were 
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diminished in vehicle treated Nf1flox/-;Col2.3Cre mice, were significantly increased 
following SD-208 treatment (Figure 29F). In summary, the striking response of 
Nf1flox/-;Col2.3Cre mice to TβRI kinase inhibition, even as compared to WT 
animals that were also receiving SD-208 treatment, substantiates the pivotal role 
of aberrant TGF-β signaling in the pathogenesis of NF1 associated osteopenia 
and osteoporosis in a mouse model that closely recapitulates the human 
disease. 
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Figure 29. TβRI inhibition restores bone mass in Nf1flox/-;Col2.3Cre mice. (A) 
The percentage change in BMD of the distal femur was determined by pDEXA 
measurements before and after four weeks treatment with vehicle or SD-208. n = 
7-12. *P ˂ 0.05, **P ˂ 0.01, ***P ˂ 0.001. (B) Representative μCT reconstructed 
femora in longitudinal (top) and transverse (bottom) cross-sections following four 
weeks treatment with vehicle or SD-208 treatment. (C) Trabecular bone volume 
fraction (BV/TV), connectivity density (Conn. D.), trabecular number (Tb.N), and 
trabecular spacing (Tb.Sp) were quantified by μCT in femora following four 
weeks treatment with SD-208 (60 mg/kg/day) as compared to vehicle control. n = 
7-12. *P ˂ 0.05, **P ˂ 0.01, ***P ˂ 0.001. (D) Representative longitudinal 
sections of H&E stained femora (25x magnification) are shown. (E) 
Representative longitudinal sections of trichrome stained femora (25x 
magnification) are shown. (F) Osteoblast numbers on the bone surface 
(Ob.N/BS) were counted manually on H&E stained sections at 200x 
magnification. n = 7-12. *P ˂ 0.05, **P ˂ 0.01 ***P ˂ 0.001. 
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Pseudarthrosis of the tibia is associated with significant morbidity in NF1 
patients. This clinical feature is also recapitulated in Nf1flox/-;Col2.3Cre mice [78]. 
Immunohistochemical analysis of Nf1flox/-;Col2.3Cre mice with tibial fracture non-
union revealed approximately three-fold increased levels of pSmad-2 within the 
fracture site as compared to WT controls (Figure 30A). If aberrant TGF-β 
signaling indeed underlies recalcitrant bone healing in NF1, we reasoned that 
pharmacologic TβRI blockade might prevent tibial fracture non-union in Nf1flox/-
;Col2.3Cre mice. To test this hypothesis, cohorts of Nf1flox/-;Col2.3Cre mice were 
treated with SD-208 (60 mg/kg/day) or vehicle control for six weeks following 
tibial fracture. Compared to healthy WT mice, which exhibited robust callus 
formation, radiographic monitoring demonstrated persistent fracture non-union in 
Nf1flox/-;Col2.3Cre mice treated with the vehicle control, with minimal or complete 
absence of callus formation at the fracture site (Figure 30B). Administration of 
SD-208 in Nf1flox/-;Col2.3Cre mice substantially enhanced callus formation as 
compared to those receiving vehicle treatment. µCT evaluation of callus 
structural integrity further revealed a significant increase in the callus bone 
volume/tissue volume ratio (BV/TV) in Nf1flox/-;Col2.3Cre mice undergoing SD-
208 treatment (Figure 30C), suggesting that pharmacologic TβRI inhibition 
improved bone formation within the fracture site. Histological sectioning (Figure 
30D) revealed fibrous tissue and an increased presence of TRACP positive 
staining osteoclasts within the fracture site of Nf1flox/-;Col2.3Cre mice receiving 
vehicle treatment. SD-208 treatment significantly reduced osteoclast numbers 
(Figure 30E) and p-Smad2 levels (Figure 30F) within the fracture callus. 
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Collectively, these results provide the first direct evidence that pharmacologic 
TGF-β blockade is an effective therapeutic strategy to augment bone healing in a 
mouse model of NF1 tibial pseudarthrosis. 
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Figure 30. TβRI inhibition prevents tibial fracture non-union in Nf1flox/-
;Col2.3Cre mice. (A) Immunohistochemical staining for p-Smad2 in fracture 
calluses of WT and Nf1flox/-;Col2.3Cre mice. The p-Smad2 positive staining area 
was normalized to the tissue area and compared between genotypes. n = 6. **P 
˂ 0.01. (B) Radiographs showing tibial fracture healing in WT controls and Nf1flox/-
;Col2.3Cre mice treated with either vehicle or SD-208 (60mg/kg/day) for six 
weeks. (C) (Top panel) Representative μCT reconstructed whole callus and 
longitudinal cross-sections from Nf1flox/-;Col2.3Cre mice treated with either 
vehicle or SD-208 for 4 wks following tibial fracture. (Bottom panel) Callus bone 
volume fraction (BV/TV) was quantified by μCT as shown in the bar graph. n = 6-
8. *P ˂ 0.05. (D) Representative tibial fractures in longitudinal cross-section 
stained with H&E (25x magnification), trichrome (100x, magnification), and 
TRACP (50x magnification). (E) The fold change in osteoclast number (Oc.N) per 
millimeter of bone surface (BS) was determined by manually counting 
multinucleated TRACP positive cells. n = 6. *P ˂ 0.05. (F) Tibial fracture sections 
were immunostained for p-Smad2. The number of p-Smad2 positive cells was 
quantified as a percentage of the total cells per high power field. n = 5-6. *P ˂ 
0.05. 
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Hypersecretion of MMP-2/9 potentiates latent TGF-β1 activation 
In order for TGF-β1 to bind to its receptors and exert its biological effects, 
it must first be cleaved from its latency associated peptide (LAP). When we 
measured the levels of latent, LAP-bound TGF-β1 versus active TGF-β1 in 
Nf1flox/-;Col2.3Cre mice with tibial fracture non-union, we observed a dramatic 
increase in the ratio of active-to-latent TGF-β1 within the facture site as 
compared to WT controls (Figure 31A), implying that accelerated conversion of 
latent TGF-β1 to the active form may play an important role in upregulating the 
bioavailability of active TGF-β1. Cleavage of the TGF-β latency associated 
peptide (LAP) is known to occur through both acid and enzymatic mechanisms 
[139]. Among these, MMP-2 and MMP-9 have been shown to mediate the 
proteolysis of LAP and play an important role in bone remodeling and fracture 
healing in animal models [162-165]. We next measured the levels of active 
MMPs in the conditioned medium of Nf1 haploinsufficient myeloid cells by gelatin 
zymography. In particular, the gelatinase activity of MMP-2/9 were significantly 
enhanced in Nf1+/- myeloid conditioned medium versus WT controls (Figure 31B). 
We observed similar upregulation of active MMP-2/9 in the serum of a NF1 
patient as compared to a matched, healthy control (Figure 31C). To demonstrate 
that only the active form of TGF-β1 can promote hyperactivation of the canonical 
Smad pathway, we transfected Nf1 nullizygous osteoprogenitors with a Smad 
luciferase reporter construct and subsequently stimulated the transfected cells 
with either recombinant, active TGF-β1 (1 ng/mL) or 100 times the dose of latent, 
LAP-bound TGF-β1 (100 ng/mL). Expectedly, Smad luciferase reporter activity 
215 
was nearly 75% greater in Nf1-/- osteoprogenitors stimulated with recombinant 
active TGF-β1 as compared to WT controls, but not in cells stimulated with LAP-
TGF-β1 (Figure 31D). Taken together, the results of this study suggest a working 
model (Figure 31E) in which genetic inactivation of Nf1 results in systemically 
increased TGF-β1 levels. Excess quantities of latent, LAP-bound TGF-β1, 
sequestered in the bone matrix, are released by bone resorbing osteoclasts and 
excessively converted to the active form by MMP-2/9 mediated cleavage of LAP. 
Active TGF-β1 feeds back through p21-Ras-dependent hyperactivation of the 
canonical Smad pathway to perpetuate a cycle of accelerated osteoclast bone 
lytic activity, while simultaneously inhibiting osteoblast differentiation which would 
be required to initiate a compensatory anabolic response. Pharmacologic 
blockade of TβRI kinase activity (SD-208) disrupts this pathological circuitry, 
restoring bone mass and preventing tibial fracture non-union in Nf1flox/-;Col2.3Cre 
mice recapitulating the human disease. 
216 
 
Figure 31A 
217 
 
Figure 31B 
218 
 
Figure 31C 
219 
 
Figure 31D 
220 
 
Figure 31E 
221 
Figure 31. Hypersecretion of MMP-2/9 promotes excessive latent TGF-β1 
activation. (A) Active TGF-β1, latency associated peptide (LAP)-bound TGF-β1, 
and β-actin were detected by western blot in protein extracts from the fracture 
site of Nf1flox/-;Col2.3Cre mice with tibial fracture non-union and WT controls. The 
bar graph above represents the fold change in the active TGF-β1/LAP-TGF-β1 
ratio. n = 5-6. (B) Activity levels of MMP-2/9 were measured in WT and Nf1+/- 
myeloid cell conditioned medium by zymography. n = 3. (C) Activity levels of 
MMP-2 and -9 were measured by zymography in the serum of a NF1 patient 
(NF1) and a matched, healthy control. (D) Osteoprogenitors transfected with a 
Smad luciferase reporter were stimulated with recombinant, active TGF-β1 (1 
ng/mL) and latent, LAP-TGF-β1 (100 ng/mL) for 18 hours. n = 3. *P < 0.05, **P < 
0.01. (E) Working model of NF1 skeletal defects mediated by a pathological cycle 
of increased TGF-β1 expression, activation, and Smad signaling. 
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Discussion 
The precise role of TGF-β1 in regulating skeletal homeostasis has been 
historically difficult to define. Observations that exogenously administered TGF-
β1 can stimulate bone formation [135, 140, 156] implicate TGF-β1 as an anabolic 
factor in bone metabolism.  Conversely, recent genetic [95, 102] and 
pharmacologic [113, 114] data demonstrate that attenuation of endogenous TGF-
β1 signaling may in fact augment bone mass and quality by simultaneously 
enhancing osteoblast differentiation while inhibiting osteoclast recruitment. Here, 
we demonstrate that hyperactive TGF-β1 signaling plays a pivotal role in the 
pathogenesis of fracture non-union and osteoporosis in a mouse model of the 
common autosomal dominant genetic disorder, neurofibromatosis type 1 (NF1). 
Previous genetic studies suggest that either overabundance or deficiency 
of TGF-β1 can lead to poor bone quality. TGF-β1 knockout mice exhibit reduced 
bone mineral density, cortical thickness, and fracture toughness [98, 99]. By 
contrast, mice over-expressing TGF-β in osteoblasts show gene dosage 
dependent reductions in bone mineral concentration, elastic modulus, and 
hardness [95]. Tang and colleagues recently established a murine model that 
carries a Camurati-Engelmann disease (CED)-derived mutant TGF-β1 [94]. 
These TGF-β1 mutant mice demonstrate high levels of active TGF-β1 and exhibit 
progressive diaphyseal dysplasia similar to that seen in patients with CED [94]. 
Similarly, individuals with Loeys-Dietz and Marfan Syndrome, both of which 
involve altered TGF-β signaling, exhibit characteristic skeletal manifestations 
including osteopenia [116, 117, 120-122], scoliosis [115, 123, 166], and an 
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increased incidence of pseudarthrosis following orthopedic instrumentation [167, 
168]. It has been hypothesized that chronically elevated serum TGF-β levels may 
also underlie bone loss in states such as hepatic and/or renal osteodystrophy 
[169]. 
Here, we show that Nf1flox/-;Col2.3Cre mice exhibit five- to six-fold elevated 
serum TGF-β1 levels as compared to WT controls. Serum TGF-β1 levels were 
similarly increased in a cohort of human NF1 patients. Consistent with these 
data, we previously reported that Nf1 haploinsufficient mast cells hypersecrete 
TGF-β, perpetuating excessive fibroblast proliferation and collagen synthesis 
within the neurofibroma microenvironment [89]. More recently, Wang and 
colleagues noted increased TGF-β mRNA levels in the fracture calluses of mice 
harboring conditional Nf1 nullizygous osteoblasts [76]. 
Beyond merely overexpressing TGF-β1, Nf1 mutant osteoblasts and 
osteoclasts pathologically differentiated and excessively resorbed bone in 
response to TGF-β1. These cellular dysfunctions were associated with increased 
activation of the canonical Smad pathway. Re-expression of the human, full-
length NF1 GRD in Nf1 deficient osteoprogenitors attenuated TGF-β1 expression 
levels and inhibited Smad phosphorylation in response to TGF-β1 stimulation; 
thus, validating that TGF-β1 mediated biochemical gain-in-functions within 
neurofibromin deficient bone cells occur in a p21-Ras-dependent fashion. 
 The elevated ratio of active-to-latent TGF-β1 in Nf1flox/-;Col2.3Cre mice 
with tibial fracture non-union further suggests that accelerated cleavage of the 
TGF-β1 latency associated peptide (LAP) may also play an important role in 
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upregulating the bioavailability of active TGF-β1 within the bone matrix. Several 
factors are known to activate latent TGF-β including integrins [170], 
thrombospondin-1[171], and MMP-2/9 [172]. In the present study, we found 
increased levels of active MMP-2 and MMP-9 in both the conditioned media of 
Nf1 haploinsufficient myeloid cells and the serum of a human NF1 patient as 
compared to controls. Intriguingly, genetic ablation of MMP-2 and MMP-9 has 
been shown to alter bone remodeling [165] and fracture repair [162, 164]. 
Moreover, patient-derived hypertrophic non-union fracture tissue was also found 
to overexpress MMP-7 and MMP-12 in a recent clinical study [163]. Collectively, 
these findings suggest need for further investigation regarding the relationship 
between MMPs and TGF-β1 activation in normal and Nf1-deficient bone healing. 
Recent clinical studies [70, 71, 80] and animal models [69, 76-79, 138, 
141] suggest that cooperative interactions between local Nf1-nullizygous  
osteoprogenitors and Nf1 haploinsufficient osteoclasts of the bone marrow play a 
critical role in modulating the disease process. By restoring the balance of 
coordinated osteoclast and osteoblast activity in NF1, attenuating TGF-β 
signaling may hold advantages over traditional monotherapies such as 
bisphosphonates, PTH, BMP, or vitamin D which selectively target either the 
osteoclast or the osteoblast alone. Furthermore, Heervä and colleagues recently 
demonstrated that osteoclasts derived from human NF1 patients were insensitive 
to bisphosphonate treatment versus healthy controls, reinforcing the need to 
develop novel targeted therapies designed specifically for the NF1 patient 
population [173]. Here, we show that suppression of hyperactive TGF-β signaling 
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can normalize the dysregulated functioning of Nf1 deficient osteoblasts and 
osteoclasts, thereby restoring bone mass and preventing tibial fracture non-union 
in Nf1flox/-;Col2.3Cre mice. These results underscore the need for next 
generation, highly selective TGF-β pharmacological inhibitors that could 
effectively treat the current therapy-resistant bone pathologies of NF1 patients. 
In summary, this study provides direct pre-clinical evidence that 
dysregulated TGF-β signaling underlies osteoporosis and non-union fracture in a 
mouse model of NF1. These in vivo data also verify the regulatory role of TGF-β 
signaling in osteoclast and osteoblast biology – a complex topic that has been 
historically difficult to assess due to biphasic and dose-dependent effects of TGF-
β on bone cells in in vitro culture. The marked response of Nf1flox/-;Col2.3Cre 
mice to pharmacologic TGF-β inhibition , even as compared to WT controls also 
undergoing treatment , underscores the critical importance of the TGF-β pathway 
in the genesis of NF1-associated bone defects and as a target for therapeutic 
intervention. Given that current treatment outcomes for pseudarthrosis in NF1 
remain poor, the potential application of pharmacologic TGF-β inhibitors to 
augment bone union warrants further pre-clinical and early phase clinical trials. 
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CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
NF1 skeletal abnormalities such as osteoporosis, dystrophic scoliosis, and 
pseudarthrosis are associated with significant morbidity. To develop robust 
targeted therapies to effectively treat these deficits, it is necessary to expand our 
understanding of the cellular and molecular pathogenesis of NF1 associated 
osseous defects. To this end, we have shown that Nf1flox/-;Col2.3Cre mice, 
harboring Nf1 nullizygous osteoblasts on a Nf1+/- background, closely 
recapitulate multiple boney manifestations seen in the human disease including 
runting (short stature), bone mass deficits, spinal deformities, and tibial fracture 
non-union. As such, this model provides a valuable platform for investigating the 
consequences of Nf1 gene dose in bone biology as well as for the preclinical 
testing of novel targeted therapeutics. 
As compared to the overt osseous phenotypes observed in Nf1flox/-
;Col2.3Cre mice, the absence of similar findings in WT, Nf1+/-, or even 
Nf1flox/flox;Col2.3Cre mice further led us to reason that cooperative interactions 
between Nf1 null osteoblasts and at least a subset of Nf1+/- lineages within the 
bone microenvironment are likely pivotal in the pathogenesis of these osseous 
features. Through a series of adoptive bone marrow transfer experiments, we 
have shown that Nf1 haploinsufficiency in hematopoietic derived osteoclasts and 
myeloid progenitors is required for the genesis of tibial fracture non-union in 
Nf1flox/-;Col2.3Cre mice. The paradigm that NF1 associated pseudarthrosis 
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involves the heterotypic interaction of multiple cell types with varying NF1 gene 
dose is consistent with analogous observations in mouse models of at least two 
other NF1 related pathologies. (1) Optic nerve glioma formation in mice has been 
shown to require both Nf1 nullizygosity in astrocytes together with Nf1 
haploinsufficiency in the microglia within the adjacent brain parenchyma [139, 
140]. (2) Yang and colleagues demonstrated that Nf1-depedent plexiform 
neurofibroma genesis in Nf1flox/-;Krox20-Cre mice requires the cooperative 
interaction of Nf1-/- Schwann cell precursors and Nf1 heterozygous mast cells in 
the tumor microenvironment [84]. 
Conditional ablation of a single Nf1 allele in myeloid progenitors versus 
mature, terminally differentiated osteoclasts has also proven informative 
regarding the stage of myeloid/osteoclast development at which Nf1 
haploinsufficiency is permissive of increased osteolytic activity. While 
Nf1flox/+;LysMCre mice exhibit increased osteoclast progenitor frequency (CFU-
M), enhanced osteoclast formation, and accelerated bone loss following 
ovariectomy induced pro-resorptive challenge, Nf1flox/+;CtskCre mice did not 
show signs of increased osteolytic activity as compared to WT controls in 
analogous experiments. Collectively, these data provide genetic evidence that 
haploinsufficiency of Nf1 in myeloid progenitors, but not terminally differentiated 
osteoclasts alone, is required to expand the pool of osteoclast progenitors, 
thereby augmenting bone resorptive capacity in vivo. 
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Our studies indicate that the cellular mechanisms of Nf1 osseous 
dysplasia are complex and may require the cooperative interaction of Nf1 
nullizygous osteoblasts and/or progenitors, as well as Nf1 heterozygous 
osteoclasts and their myeloid precursors. These observations led us to consider 
cytokines such as TGF-β1, which function as master regulators in the 
spatiotemporal coupling of osteoblast and osteoclast activity [94], as potential 
molecular mediators of NF1 bone defects. We were alerted to this possibility by 
our previous observation that Nf1 haploinsufficient myeloid cells potentiate 
neurofibroma phenotypes through secreted TGF-β signaling [89]. More 
intriguingly, characteristic NF1 osseous defects such as scoliosis, osteopenia, 
tibial dysplasia, and pseudarthrosis are frequently observed in a number of other 
clinical disorders associated with dysregulated TGF-β signaling, including Loeys-
Dietz syndrome [115-118], Marfan syndrome [119-123], and Camurati-
Engelmann disease [124]. 
Here, we provided genetic and pharmacologic evidence that hyperactive 
TGF-β1 signaling pivotally underpins osseous defects in Nf1flox/-;Col2.3Cre mice. 
Compared to controls, serum TGF-β1 levels were five- to six- fold increased both 
in Nf1flox/-;Col2.3Cre mice and in a cohort of NF1 patients. Nf1 deficient 
osteoblasts, the principal source of TGF-β1 in bone, overexpressed TGF-β1 in a 
gene dosage dependent fashion. Moreover, Nf1 deficient osteoblasts and 
osteoclasts were hyperresponsive to TGF-β1 stimulation, potentiating osteoclast 
bone resorptive activity while inhibiting osteoblast differentiation. These cellular 
phenotypes were further accompanied by p21-Ras-dependent hyperactivation of 
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the canonical TGF-β1-Smad pathway. Re-expression of the human, full-length 
neurofibromin GTPase-activating protein (GAP) related domain (NF1 GRD) in 
primary Nf1 deficient osteoblast progenitors, attenuated TGF-β1 expression 
levels and reduced Smad phosphorylation in response to TGF-β1 stimulation. As 
an in vivo proof of principle, we demonstrated that administration of the TβRI 
kinase inhibitor, SD-208, could rescue bone mass deficits and prevent tibial 
fracture non-union in Nf1flox/-;Col2.3Cre mice. In sum, these data demonstrate a 
pivotal role for hyperactive TGF-β1 signaling in the pathogenesis of NF1 
associated osteoporosis and pseudarthrosis. Importantly, they implicate the TGF-
β signaling pathway as a potential therapeutic target in the treatment of NF1 
osseous defects which are refractory to current therapies. 
A number of pharmacologic TGF-β inhibitors are currently in early phase 
clinical trials for the treatment of idiopathic pulmonary fibrosis, focal segmental 
glomerulosclerosis, and various malignancies [174]. Despite promising 
responses, the ubiquitous role of TGF-β in regulating multiple physiological 
processes such as the immune system and cardiovascular development has 
raised concerns regarding the potential side effects of these drugs when 
administered systemically at high doses and for extended durations. Skin lesions, 
including eruptive non-malignant keratoacanthomas and squamous cell 
carcinoma, gingival bleeding, and fatigue were among the most commonly 
reported side-effects in metastatic melanoma patients receiving extended dosing 
at 10-15 mg/kg with the pan monoclonal TGF-β neutralizing antibody, GC-1008 
[175]. In a dose escalation study of the small molecule TβRI kinase inhibitor, 
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LY2157299, for the treatment of refractory malignant glioma, pulmonary 
embolism and thrombocytopenia were dose-limiting toxicities observed during 
the second treatment cycle; however, no indications of cardiovascular toxicity 
were reported [176]. 
To circumvent adverse effects of systemic TGF-β inhibition, one potential 
strategy would be to utilize targeted drug delivery systems to limit drug 
bioavailability to the tissue of interest. Bisphosphonates [177, 178] and 
oligopeptides, such as repeating sequences of aspartate-serine-serine 
(AspSerSer)6 [179], are two classes of stable bone-targeting moieties that have 
been utilized to deliver therapeutic agents to skeletal tissues. To achieve 
sustained drug release within a localized anatomical compartment, encapsulation 
of compounds in nanoparticles and/or polymeric scaffolds might serve as useful 
delivery vectors [180, 181]. Collagen sponges infused with recombinant BMPs 
are one particularly common application of this technology which has been used 
by orthopedic surgeons for the past decade to promote bone healing in spinal 
fusion, fracture non-union, and critical sized long-bone defects [182]. Ultimately, 
further testing of clinical grade pharmacologic TGF-β inhibitors optimized for 
targeted delivery to bone needs to be undertaken in NF1 murine pseudarthrosis 
models to facilitate clinical translation into patients. 
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Future directions 
Although pharmacologic TGF-β inhibition successfully rescued bone mass 
deficits and prevented tibial fracture non-union in Nf1flox/-;Col2.3Cre mice, its off-
target effects on hematopoietic cells and other tissues remain a limiting factor for 
clinical translation in the treatment of NF1 patients with pseudarthrosis or 
osteoporosis. The characterization of specific downstream targets which are 
critical to modulating the physiological effects of TGF-β in osteoblasts and 
osteoclasts is now the primary focus of our ongoing research. We are currently 
working to identify transcription factors which selectively modulate aberrant 
cellular functions in Nf1 mutant osteoclasts and osteoblasts induced by TGF-β1 
stimulation. Ultimately, therapeutic modulation of such targets may provide novel 
treatment strategies for pseudarthrosis and other therapy resistant osseous 
manifestations of NF1. 
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